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Differentiation, And Disease
Abstract
The intestinal epithelium is a continuously self-renewing tissue that must balance its function as the site
of nutrient absorption with its role as a barrier between the body and the external environment. With its
high cellular turnover and continual exposure to lumenal antigens, the intestinal epithelium is highly
susceptible to developing diseases, such as inflammatory bowel disease (IBD) and cancer. Understanding
the factors that control intestinal epithelial development are key to discovering disease etiology and to
engineering new treatments. In mammals, studies have pointed to dysregulation of RNA Polymerase III as
playing a role in oncogenic transformation. A deletion in the gene encoding Polr3b, a Pol III subunit,
impairs development of the intestinal epithelial progenitor cells in zebrafish. Thus, I hypothesized that
POLR3B also has an important role in the mammalian intestinal epithelium. I characterized mice
expressing an intestinal epithelium-specific hypomorphic Polr3b mutation. Neonatal Polr3b mutants have
severely reduced survival and growth, reduced intestinal epithelial proliferation, and lack normal crypt
development. Thus, Pol III is essential for the establishment of the intestinal epithelium in mice. Given
that normal Pol III is required for adequate protein production in order to sustain the high rate of
proliferation in mammalian gut, this enzyme is a questionable target for cancer drugs. It was reported that
Mucin2 (Muc2), the main component of intestinal mucus, is a direct transcriptional target of FOXA1 and
FOXA2 in the mouse intestinal epithelium. I hypothesized that in addition to Muc2, the FOXA factors
transcriptionally regulate other genes that are required for the maintenance of the intestinal mucosa. The
Foxa1/a2-deficient colonic epithelium in mice of advanced age (>7 months) displays increased
susceptibility to spontaneous colitis. I performed FOXA1 and FOXA2 chromatin immunoprecipitation
assays followed by ultra-high throughput sequencing (ChIP-Seq) analysis on wild type mouse colonic
crypts, as well as RNA-seq on Foxa1/a2-deficient and control aged colon. Of the FOXA1/A2-bound,
differentially expressed genes, glycosyltransferases were overrepresented, including the IBD risk gene
Fut2, which was downregulated in mutant colon.
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ABSTRACT
MODULATION OF TRANSCRIPTION IN THE MURINE GUT EPITHELIUM IN DEVELOPMENT,
DIFFERENTIATION, AND DISEASE
Julia Kieckhaefer
Klaus H. Kaestner

The intestinal epithelium is a continuously self-renewing tissue that must balance its function as
the site of nutrient absorption with its role as a barrier between the body and the external
environment. With its high cellular turnover and continual exposure to lumenal antigens, the
intestinal epithelium is highly susceptible to developing diseases, such as inflammatory bowel
disease (IBD) and cancer. Understanding the factors that control intestinal epithelial development
are key to discovering disease etiology and to engineering new treatments. In mammals, studies
have pointed to dysregulation of RNA Polymerase III as playing a role in oncogenic
transformation. A deletion in the gene encoding Polr3b, a Pol III subunit, impairs development of
the intestinal epithelial progenitor cells in zebrafish. Thus, I hypothesized that POLR3B also has
an important role in the mammalian intestinal epithelium. I characterized mice expressing an
intestinal epithelium-specific hypomorphic Polr3b mutation. Neonatal Polr3b mutants have
severely reduced survival and growth, reduced intestinal epithelial proliferation, and lack normal
crypt development. Thus, Pol III is essential for the establishment of the intestinal epithelium in
mice. Given that normal Pol III is required for adequate protein production in order to sustain the
high rate of proliferation in mammalian gut, this enzyme is a questionable target for cancer drugs.
It was reported that Mucin2 (Muc2), the main component of intestinal mucus, is a direct
transcriptional target of FOXA1 and FOXA2 in the mouse intestinal epithelium. I hypothesized
that in addition to Muc2, the FOXA factors transcriptionally regulate other genes that are required
for the maintenance of the intestinal mucosa. The Foxa1/a2-deficient colonic epithelium in mice of
advanced age (>7 months) displays increased susceptibility to spontaneous colitis. I performed
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FOXA1 and FOXA2 chromatin immunoprecipitation assays followed by ultra-high throughput
sequencing (ChIP-Seq) analysis on wild type mouse colonic crypts, as well as RNA-seq on
Foxa1/a2-deficient and control aged colon. Of the FOXA1/A2-bound, differentially expressed
genes, glycosyltransferases were overrepresented, including the IBD risk gene Fut2, which was
downregulated in mutant colon.
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CHAPTER 1

INTRODUCTION
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Inflammatory bowel disease
Due to the similarity in clinical manifestation of ulcerative colitis (UC) and Crohn’s disease, the
two conditions are commonly referred to under the umbrella term ‘inflammatory bowel disease’
(IBD) (Danese and Fiocchi, 2011). Both are chronic conditions with periods of remission and
relapse that present clinically with abdominal pain, chronic, bloody diarrhea, fever, and weight
loss. Histopathologically, common features of UC and Crohn’s disease in the colon are altered
crypt morphology, goblet cell loss, and ulcerations. Complications of IBD include intestinal
bleeding and anemia, peripheral arthritis, ocular and skin conditions, and especially after
prolonged disease, dysplasia and colorectal cancer (Danese and Fiocchi, 2011; Torres et al.,
2016).
Despite their similarities, UC and Crohn’s disease are distinct diseases that affect
different regions of the gut. Inflammation in ulcerative colitis is usually restricted to the colon and
stays within the mucosal layer, which may be explained by autoimmune targeting of colonocytes.
Circulating IgG1 antibodies against an epithelial antigen that is shared by the colon, eyes, skin,
joints, and biliary epithelium may result in autoimmune damage to the colon while also explaining
the extraintestinal features of the disease (Danese and Fiocchi, 2011). However, all segments of
the gastrointestinal tract can be affected in Crohn’s disease, though the most commonly inflamed
areas are the terminal ileum and colon. In Crohn’s disease, inflammation occurs transmurally and
in segments, forming a pattern that is often called “cobblestoning” (Baumgart and Sandborn,
2012; Torres et al., 2016).
Despite these differences, there is strong overlap in the approach to treating and
managing the two diseases. Common medical treatments for IBD are anti-inflammatory drugs
such as sulfasalazine and 5-aminosalicylate, glucocorticoids, and infliximab, a monoclonal
antibody directed against TNF-α. However, though antibiotics are a successful treatment for
luminal Crohn’s, they have not been shown to be an effective treatment for UC (Torres et al.,
2016). Failure of medical treatments may indicate colectomy, which can be curative for UC, but
not for Crohn’s disease (Baumgart and Sandborn, 2012; Danese and Fiocchi, 2011; Torres et al.,
2016). Nevertheless, surgery is often required to treat intestinal complications from Crohn’s
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disease, such as strictures, abscesses, and fistulas, which have a high rate of postoperative
recurrence (Baumgart and Sandborn, 2012). Thus, IBD is a lifelong condition that requires
constant management.

Disease epidemiology and environmental factors
th

Since the mid-20 century, the incidence of IBD has been increasing in developed countries, with
the highest prevalence seen in Northern Europe and North America (Ananthakrishnan, 2015;
Danese and Fiocchi, 2011). As of 2015, an estimated 1.3% of adults (3.1 million people) had
been diagnosed with IBD in the United States. Americans with the highest rate of IBD are aged
65 or older (1.7%). IBD is also more prevalent in urban populations, among people who did not
complete high school, and in those that fall below the poverty line (Dahlhamer et al., 2016). The
differences in disease incidence between socioeconomic groups point to lifestyle characteristics
as having a major impact on disease risk.
Numerous environmental factors associated with a westernized lifestyle are thought to
increase the risk of developing IBD, including a diet high in fat and sugar and low in dietary fiber,
smoking, medication use, and stress. Environmental factors during childhood may also have an
impact on disease development, such as breastfeeding and exposure to animals, which may be
protective, and antibiotic use, which may increase disease risk (Ananthakrishnan, 2015; Danese
and Fiocchi, 2011; Torres et al., 2016). In support of the role the environment and lifestyle play in
disease risk, the incidence of IBD has been rising in Asia in parallel with its economic
development, which coincides with a shift towards a westernized lifestyle (Ananthakrishnan,
2015; Torres et al., 2016). Further evidence for this notion comes from the fact that firstgeneration and second-generation Indian migrants to the UK are diagnosed with IBD at rates that
are higher than the IBD incidence in India and more similar to the rate of diagnosis among native
residents of the UK. Concordantly, Africa and South America still have low rates of IBD, though
there is some evidence that the incidence may be increasing (Ananthakrishnan, 2015).

Genetic determinants of IBD risk
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Although environmental factors play a prominent role in disease risk, development of disease
cannot be explained by these factors alone. There is ample evidence that genetic components
make a significant contribution to disease etiology. One of best pieces of evidence for IBD
heritability is the significantly higher concordance rate among monozygotic than dizygotic twins
for IBD (Orholm et al., 2000). Another well-known substantiator of the genetic basis of IBD is the
high rate of IBD in Ashkenazi Jews, which is not observed within other ethnic groups (Roth et al.,
1989). Finally, there are numerous family studies that have shown that first-degree relatives of an
affected proband are more likely to develop the disease themselves (Russell and Satsangi,
2004). With mounting evidence for a genetic contribution to disease, studies continue to be
undertaken to identify new disease risk loci.
IBD is a complex disease with evidence pointing to numerous causal genes. One of the
earliest Crohn’s susceptibility loci to be identified was associated with the pattern recognition
receptor NOD2/CARD15, an activator of the transcriptional regulator NFκB, which reinforced the
hypothesis that Crohn’s disease is caused by an altered response to intestinal pathogens (Hugot
et al., 2001). Significantly, the cytokine gene IL10, which when ablated in mice serves as a model
for IBD (Berg et al., 1996), is a disease risk locus for both Crohn’s and UC (Franke et al., 2008,
2010). A genome-wide association study (GWAS) of Crohn’s disease identified a strong
association of the FUT2 null allele W143X with the development of Crohn’s disease. The
association of W143X, which is protective against norovirus infection but increases the risk of
Crohn’s disease, strengthens the hypothesis that altered host-microbe interactions in the gut play
a role in disease etiology (Franke et al., 2010; McGovern et al., 2010).
To date, GWAS has identified over 200 IBD risk loci (Franke et al., 2010; Jostins et al.,
2012; Liu et al., 2015). Of the 163 loci identified by a meta-analysis of 15 Crohn’s disease and
ulcerative colitis GWA studies (Jostins et al., 2012), 110 are associated with both diseases,
indicating that many mechanisms of pathogenesis in one disease have some kind of role in the
other. However, risk alleles at two Crohn’s disease loci, PTPN22 and NOD2, are protective in UC,
strong evidence for differences in etiology between the two diseases. However, the autoimmune
diseases ankylosing spondylitis and psoriasis have a high enrichment of overlap with IBD loci.
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Genes that are associated with the overlapping loci are largely involved in T cell regulation,
supporting the idea that IBD is an autoimmune condition. Gene Ontology enrichment analysis of
the genes associated with the 163 loci revealed that the most significantly enriched terms were
“regulation of cytokine production” and “lymphocyte activation”, though “response to molecules of
bacterial origin” was also significantly enriched (Jostins et al., 2012).

Mouse models of IBD
Much of what is known about the molecular pathogenesis of IBD comes from the study of mouse
models, which has led to a better understanding of the complex role that modulation of the
immune response has in disease etiology. Two of the oldest animal models of colitis chemically
induce mucosal irritation by the administration of either dextran sulfate sodium (DSS) (Okayasu et
al., 1990) or 2,4,6-trinitrobenzenesulfonic acid (TNBS) (Morris et al., 1989). In both the DSS and
TNBS models, there is evidence that hyperresponsiveness to antigens in the mucosal microflora
plays a critical role in the development of colitis. In DSS-treated animals with a deficiency for
trefoil factor 3 (Tff3) (formerly intestinal trefoil factor, Itf), a protein important for the maintenance
and healing of the epithelium, colitis is more severe than in normal mice (Mashimo et al., 1996).
Furthermore, changes in barrier function in DSS-treated mice have been observed before the
onset of DSS-induced inflammation, suggesting that a breakdown in the epithelial barrier is
exposing mucosal antigens (Strober et al., 2002). Whereas T cells are normally unresponsive to
the resident microbial flora, in mice with TNBS-colitis, tolerance to microbial antigens of
commensal bacteria is lost (Duchmann et al., 1999). In addition to determining the importance of
gut microbes for the initiation of enterocolitis, the TNBS model also helped to establish the
requirement of cytokine dysregulation in disease progression. Notably, TNBS-mediated
inflammation could not be induced in TNF-α-deficient mice, and administration of anti-IL-12
antibody prevented TNBS-induced colitis (Strober et al., 2002). Although cytokine dysregulation
in the DSS and TNBS models is required for the induction of colitis, resident gut microbes are
likely to be an important factor as well.
Gene targeting models have allowed for the dissection of immune regulatory pathways by
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enabling the ablation of individual cytokines and immune cell receptors. The T cell receptor (TCR)
α and β (Mombaerts, 1993) and the Interleukin-2 (IL-2) (Sadlack et al., 1993) deficient models
both support the hypothesis that the immune system plays a primary role in the etiology of UC.
The T cell receptor is responsible for recognizing fragments of antigens bound to major
histocompatibility complex molecules. IL-2 is a cytokine produced by active T cells that plays key
roles in T cell proliferation and differentiation. Both TCR and IL-2 mutant mice developed
diarrhea, weight loss, a thickened colonic wall with altered crypt structure, a depletion of goblet
cells, and an inflammatory cell infiltrate in the lamina propria (Mombaerts, 1993; Sadlack et al.,
1993). Importantly, antibodies directed against colonic antigens were detected in IL-2 mutant
mice (Sadlack et al., 1993). Additionally, lesions were not present in the small intestine of either
model (Mombaerts, 1993; Sadlack et al., 1993). These data support the hypothesis that UC
results from an autoimmune attack on the colonic epithelium, possibly as a result of the high
microbial load of the colon creating a highly antigenic environment. Thus, immune-mediated
destruction of the colonic epithelium would lead to the production of autoantibodies, creating a
cycle of epithelial targeting and damage (Mombaerts, 1993). Despite the role of dysregulated T
cells in disease development, the presence of gut microbes was still required for the initiation of
disease. Neither TCR-α

-/-

mice nor IL-2 deficient mice raised in a germ-free environment

developed any symptoms of colitis (Dianda et al., 1997; Sadlack et al., 1993).
The hypothesis that commensal bacteria may play a role in the initiation of disease is
supported further by the timing of disease onset in mice with a targeted mutation in IL-10 (IL-10
). IL-10

-/-

-/-

mice, when kept under conventional housing conditions, spontaneously developed

chronic and highly lethal enterocolitis mainly affecting the duodenum, jejunum, and colon. When
maintained in a specific pathogen-free (SPF) environment, IL-10 mutants developed colitis that
was far less severe and only present in the proximal colon (Kuhn et al., 1993). At three weeks of
age, which is when the normal gut microbiota first begin to stabilize (Schloss et al., 2012),
inflammation was undetected in almost a third of SPF-housed IL-10

-/-

mice. However, by three

months of age, intestinal lesions were observed in all mutants, often with transmural
inflammation, hyperplasia, and crypt abscesses. Treatment of three-week-old mutants with
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injections of IL-10 was able to completely prevent the development of colitis, but treatment of
adults was unable to cure the disease (Berg et al., 1996). As IL-10 is a suppressor of
macrophage activation, disease in these mice may be caused by the inappropriate release of
inflammatory cytokines by unregulated macrophages. In that case, in young IL-10

-/-

mice,

commensal gut microbes would initiate an uncontrolled immune response, resulting in the
generation of pathogenic effector cells that produce inflammatory cytokines. However, in young
IL-10

-/-

mice lacking pathogenic microbiota, there would be no inappropriate immune response

and administration of IL-10 would prevent the development of disease. In older mice,
administration of IL-10 may not have been able to reverse the progression of inflammation
because the dysregulation of immune cells had already been established (Berg et al., 1996; Kuhn
et al., 1993). Together, these models all demonstrate the requirement for a balance between
protection against and tolerance to commensal bacteria by immune effector cells.

Gut mucus and glycosylation
The monosaccharides covalently added to specific amino acids within target proteins are
called glycans. The addition in the Golgi apparatus of a glycan to the hydroxyl (-OH) group of
serine or threonine residues, termed O-linked glycosylation, is a major form of posttranslational
modification. In the gastronintestinal tract, key components of the glycoprotein layer that protects
the lumenal cell membranes, termed the glycocalyx, are secreted and membrane-associated
mucins (Corfield et al., 2001). Mucins are a family of high molecular weight O-linked glycoproteins
that contain domains enriched with serine, threonine, and proline, termed PTS domains. The first
step of O-linked glycosylation is the addition of an N-acetylglalactosamine (GalNAc) to the
Ser/Thr residues of the PTS domains to form the Tn antigen. The Tn antigen is the foundation for
further modifications to form four main core structures, designated cores 1 through 4 (Figure 1.1).
Additional glycosyltransferases then go on to modify O-glycans, adding sugars, such as fucose
and sialic acid. Most mucin-type O-glycans are derived from core 1 and core 3 structures. Core 3derived O-glycan expression is restricted primarily to the salivary glands and the intestinal tract
(Bergstrom and Xia, 2013; Honke and Taniguchi, 2002; Iwai et al., 2002).
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Mucus covers the entire gastrointestinal tract from the mouth to the anus. In the small
intestine, a single layer of mucus is secreted from the tops of the crypts and then travels toward
the tips of the villi (Johansson et al., 2011). In the colon, there are two well-defined mucus layers:
an outer, loose layer that is inhabited by commensal bacteria, and an inner viscous layer that is
anchored to the epithelium and is sterile. As bacteria do not normally penetrate the inner mucus
layer, they are unable to interact with epithelial cells directly. The main component of mucus in
the small intestine and colon is the gel-forming mucin, Mucin-2 (MUC2) (Johansson et al., 2008).
MUC2 is heavily modified by glycans, which make up 80% of the mass of the molecule
(Bergstrom and Xia, 2013). In addition to their gel-forming function, glycans serve as both an
attachment site and an energy source for bacteria. As bacteria degrade glycans and
nondigestible food, they release short fatty acids that are taken up by the colonic epithelium and
used as an energy source (Johansson et al., 2011).

MUC2
Due to its extensive O-glycan modifications, MUC2 has a high capacity to bind water,
thus contributing to its gel-forming capability. When MUC2 is stored in mucin granules in goblet
cells, it is in a condensed form, but when the granules are released, they expand substantially in
volume (Johansson et al., 2008). The numerous chains of carbohydrates extending outward from
the protein core of MUC2 are what give the molecule what is commonly termed a “bottle brush”
appearance. In humans, the primary O-glycans found on MUC2 are core 3-derived structures,
while murine MUC2 is comprised mostly of core-1 derived O-glycans, with core 3-derived
structures making up only 1% of the modifications (Bergstrom and Xia, 2013). Muc2-deficient
-/-

mice (Muc2 ) develop intestinal inflammation and colorectal cancer (Van der Sluis et al., 2006;
Velcich, 2002).

The fucosylation pathway
L-fucose is a common component of glycoproteins in mammalian cells. Glycans are
fucosylated using the substrate guanosine diphosphate (GDP)-fucose, which is synthesized by
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two different pathways in mammals: a de novo pathway and a free fucose-dependent salvage
pathway. The de novo pathway generates fucose through the reactions of two enzymes: GDPmannose 4,6-dehydratase (GMDS) and GDP-keto-6-deoxymannose 3,5-epimerase, 4-reductase
(FX). The majority of fucose is produced through this pathway. The enzyme α(1,2)fucosyltransferase (FUT2), which modifies salivary and other epithelial secretions, is also called
the Secretor (Se) transferase (Kelly et al., 1995). FUT2 synthesizes the H blood group antigen,
which may go on to be modified to form the A or B antigens, while unmodified H antigen is
expressed in blood-type O individuals. Although A and B antigens are commonly associated with
blood type, these cell surface antigens also play a role in host-microbe interactions in the gut
(Becker and Lowe, 2003).

Glycosylation perturbations in IBD
It has long been known that the composition of glycoconjugates is perturbed in the
colonic mucosa of patients during malignant transformation (Boland et al., 1982), as well as in
patients with inflammatory bowel disease (Podolsky and Fournier, 1988). Consequently, mouse
models have been derived in order to study the effects of changes in glycosylation on the colonic
mucosa. Two well-studied examples are the B3gnt6-deficient (An et al., 2007) and the Fxdeficient mouse (Wang et al., 2016).
Mice homozygous for the B3gnt6-null allele, and thus unable to produce core 3-derived
O-glycans, produced significantly less MUC2 protein. Despite the difference in core 3-derived Oglycan composition between mice and humans, B3gnt6

-/-

mice present with IBD-like features,

including increased inflammatory cell infiltration, an increased epithelial proliferation rate, and had
an enhanced susceptibility to DSS-induced colitis. Although B3gnt6 is expressed throughout the
GI tract, the inflammatory phenotype was restricted to the colon (An et al., 2007), which is
reminiscent of human UC. Fx

-/-

mice, which have a deficiency of GDP-fucose, spontaneously

develop colitis, with increased epithelial permeability and dysplasia that progresses to
adenocarcinoma. The features of colitis in Fx-/- mice are reversible by dietary fucose
supplementation (Wang et al., 2016). The fact that small changes in glycosylation in both of these
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models resulted in colitis underlines the importance in maintaining a healthy gylcocalyx capable
of resisting infiltration by microbes.

The intestinal epithelium
The intestinal epithelium, a single cell layer that lines both the small intestine and colon, functions
both as the site of nutrient absorption and as a barrier between the underlying lamina propria and
lumenal antigens from food and commensal bacteria. In the small intestine, the epithelium forms
finger-like projections called villi that extend toward the lumen, while in both the small intestine
and the colon, the epithelium forms invaginations into the underlying mesenchyme called crypts.
In mice, villi begin to form shortly before birth when outgrowths of the underlying mesenchyme
push the pseudostratified epithelium toward the lumen. By birth, the epithelium is a single layer of
columnar cells, with depressions between the budding villi called intervillus regions (Mathan et al.,
1976). In neonates, intervillus regions are composed of polyclonal progenitor cells. However, as
mature crypts form, the polyclonal cells are displaced by a single predominant progenitor at the
crypt base. By postnatal day (P) 14, the villi are composed of bands of monoclonal cells arising
from each of their surrounding crypts (Schmidt et al., 1988).

Differentiated cell types of the epithelium
The single stem cell pool at the crypt base gives rise to all seven of the epithelial cell types:
absorptive, enteroendocrine, Paneth, goblet, microfold (M), cup, and tuft. All are found in the
small intestine, while the colon lacks Paneth cells. Except for Paneth cells, all cells in the
intestinal epithelium undergo renewal every 4-7 days, while Paneth cells are completely replaced
after two months. Additionally, Paneth cells remain at the crypt base, while enteroendocrine,
goblet, and absorptive cells, which are joined by junctional complexes, are forced as a unit toward
the villus tip by new cells that are dividing at the crypt base. The migrating cells are eventually
shed from the villus tip into the intestinal lumen (Cheng and Leblond, 1974; Gerbe et al., 2011).
Of the seven types of intestinal epithelial cells, only cup cells, which are distinguished
from absorptive cells by their unique apical cup-like morphology and lighter cytoplasmic staining,
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lack a clear function (Madara, 1982). The absorptive enterocytes, which are the most abundant
villus cell type, are responsible for taking up nutrients, while the other cell types function either in
a signaling, barrier forming, or an immunoregulatory capacity. Though enteroendocrine cells
make up only approximately 1% of the intestinal epithelial cells, the gut nevertheless constitutes
the largest endocrine organ in the body. Enteroendocrine cells modulate nutrient uptake and gut
motility by sensing the contents of the lumen and releasing hormones to initiate appropriate
responses. For example, in response to sensing lumenal amino acids, the subtype of
enteroendocrine cells called G cells release of gastrin, which then enters circulation to stimulate
the production of stomach acid (Sternini et al., 2008). Goblet cells, which make up a significant
portion of the epithelium, form the first line of defense against gut bacteria by secreting a
protective mucus layer that covers the epithelium. By secreting antimicrobial peptides Paneth
cells, which are found at the base of every small intestinal crypt, modulate the population of small
intestinal microbiota. Instead of preventing bacteria from breaching of the epithelial barrier, two of
the least abundant cell types, M cells and tuft cells, may actually have roles as an interface
between the gut microbiota and the immune cells that reside in the mesenchyme and the gutassociated lymphoid tissue (GALT) (Gerbe et al., 2012).
Recently, tuft cells were defined as being a unique cell type distinct from enteroendocrine
cells (Gerbe et al., 2011). Named for their long apical microvilli that extend into the lumen, tuft
cells have been thought to be involved in numerous functions, including chemoreception, smooth
muscle contraction, and regulation of ion transport. However, new evidence points to a role of tuft
cells in the intestinal response to epithelial parasites (Howitt et al., 2016). The first indication of a
tuft cell-specific response was observed in specific pathogen-free (SPF) mice colonized by
intestinal parasites when the abundance of tuft cells in the epithelium increased from the 0.4%
reported in conventionally housed mice (Gerbe et al., 2012) to as much as 8% in the parasitecolonized mice. Goblet cell hyperplasia and eosinophilia were also observed in the lamina propria
of the infected mice. In mice lacking expression of Trpm5, a gene required for tastechemosensory signal transduction that intestinally is primarily expressed in tuft cells, the numbers
of tuft cells, goblet cells, and eosinophils remained at the levels observed in conventionally-
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housed animals. Thus, tuft cells may detect parasites, and then in response stimulate changes in
epithelial cell differentiation, such as the protective increase in mucus production brought about
by goblet cell hyperplasia, as well as the recruitment of mucosal immune cells (Howitt et al.,
2016).
M cells comprise the follicle-associated epithelium, which is positioned directly over gutassociated lymphoid follicles. The apical surface of M cells is described as having “microfolds”,
while the basal surface forms a “pocket” that contains B and T lymphocytes and macrophages.
This interaction between the epithelial M cell and lymphocytes is thought to facilitate the delivery
of foreign materials by way of transepithelial vesicular transport to antigen presenting cells. The
influence of commensal microbiota on the composition of differentiated epithelial cells is
highlighted by the fact that germ-free mice have a reduced number of M cells, but when they are
exposed to pathogens, the number of cells differentiating into M cells increases (Neutra, 1998).
Together, the functions of tuft cells and M cells illustrate how the intestinal epithelium and the gut
microbiota interact in order to modulate both bacterial and differentiated epithelial cell
populations.

Commensal bacteria in normal gut development
The presence of commensal bacteria in the gut is mutually beneficial, as the host provides
nutrients for the bacteria and in turn, the bacteria are able to break down indigestible materials
into nutrients that can then be used by the host. Before birth, the developing mammalian gut is
sterile, but at birth mammals acquire gut microflora as they pass through the birth canal. The guts
of mice raised in a germ-free environment have several phenotypic differences from
conventionally raised mice that are reversible upon bacterial colonization, such as composition of
the intestinal glycocalyx. In conventionally raised mice, during weaning, glycoproteins undergo a
shift from being mostly terminally sialylated to being mostly terminally fucosylated. However,
without stimulation by gut bacteria, the shift in glycosyltransferase activity does not take place.
The fucose that modifies glycans is used as an energy source by commensal bacteria, therefore,
the regulation of the production of fucose may allow the host to influence the composition of the
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gut microbiome (Hooper, 2004). Another pathway by which the gut modulates the microbial
population is through the secretion antimicrobial peptides, such as angiopoietin-4 (ANG4), a
Paneth cell granule protein. During weaning in conventionally raised mice, a dramatic increase in
ANG4 is observed that does not occur in germ-free animals (Hooper et al., 2003). Additionally,
the increase in ANG4 and other angiogenin family members may stimulate villus capillary network
development. In mature germ-free mice, capillary networks do not fully develop. However, the
density of villus capillaries rapidly increases following the introduction of normal gut microbes
(Stappenbeck et al., 2002). Thus, bacterial colonization may be required to stimulate some
aspects of mammalian gut development

Signaling pathways: maintenance of stemness and differentiation
The maintenance of the intestinal epithelium relies on a balance between the proliferative and the
differentiated compartments, which is maintained through the coordination of a complex network
of signaling pathways.

Wnt signaling
Wnt proteins comprise a large family of conserved growth factors that initiate signaling cascades
to induce gene expression in multiple developmental processes throughout the body. The
canonical process of Wnt signal transduction begins when a secreted Wnt ligand binds to the
receptor complex formed by a seven transmembrane protein Frizzled (Fz) and a single-pass low
density lipoprotein receptor-related protein (LRP). The Fz-LRP transmembrane complex then
recruits and inhibits the intracellular β-catenin destruction complex, which consists of Axin,
adenomatous polyposis coli (APC), and glycogen synthase kinase 3 (GSK-3). In the absence of
Wnt signaling, this complex tags β-catenin for destruction by phosphorylating the protein, which is
then ubiquitylated and degraded by the proteasome. However, following the sequestration of the
Axin/APC/GSK-3 complex to the cell membrane following Wnt binding to its receptor, β-catenin
accumulates in the cytoplasm and is shuttled to the nucleus. Once in the nucleus, β-catenin
displaces the transcriptional repressor Groucho and partners with a complex that includes the T

13

cell-specific transcription factor/lymphoid enhancer-binding factor 1 (TCF/LEF) family of
transcription factors to initiate transcription of Wnt target genes (Gordon and Nusse, 2006).
Canonical Wnt signaling is required for maintenance of epithelial proliferation in both the
small intestine and the colon. In mice with disrupted Tcf7l2, which encodes the TCF family
member transcription factor 4 (Tcf-4), cycling intestinal epithelial cells were absent by embryonic
day 14.5, resulting in the neonatal epithelium being composed completely of differentiated cells
(Korinek,1998). In adult mice, overexpression of the secreted protein Dickkopf-1 (DKK1), which
inhibits canonical Wnt signaling by causing the internalization of the LRP coreceptor, led to the
breakdown of epithelial architecture in both the small intestine and colon (Kuhnert et al., 2004).
Conversely, constitutive activation of the Wnt pathway causes hyperproliferation of the intestinal
epithelium and the development of intestinal polyps. For example, in humans that have the
disorder familial adenomatous polyposis (FAP), as well as in the Apc

Min/+

mouse model of FAP, a

mutation in the β-catenin destruction complex gene APC prevents the phosphorylation of βcatenin. The subsequent uncontrolled transcription of Wnt target genes gives rise to the in the
development of multiple intestinal neoplasias (Min) (Su et al., 1992). Thus, the activation of Wnt
target genes modulates intestinal epithelial proliferation during development and in adulthood.
Although 19 Wnt genes are encoded in the mammalian genome, only a subset of Wnts
and their receptors are expressed in the intestine during development and in the mature
gastrointestinal tract (Gordon and Nusse, 2006). In the fetal small intestine, Wnt5a has been
detected in the mesenchyme at the tips of growing villi, while the receptors Fz5-7 are found in the
epithelium. During embryogenesis, epithelial Wnt signaling may be required for the clustering of
mesenchymal cells at the start of villus formation at E15.5, as in embryos with a conditional
deletion of the β-catenin gene Ctnn1b intestine, these clusters did not form (Chin et al., 2016).
However, interpretation of these results is complicated by the fact that β-catenin also functions as
a part of epithelial adherens junctions. In the adult intestine, the ligands Wnt3 and Wnt9b are
expressed in Paneth cells, while Wnt6 is expressed in the epithelia of small intestinal and colonic
crypts. Expression of the Fz and LRP receptors, as well as the TCF proteins, is also restricted to
the epithelium. In the mature mesenchyme, Wnt2b and Wnt5a have been detected in the villus,
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whereas Wnt5a and the related Wnt5b are both expressed in the mature colon mesenchyme.
Notably, Wnt5a is also highly upregulated in the stromal cells of Apc

Min/+

polyps (Gregorieff et al.,

2005).
Due to the multiple Wnts expressed both in the epithelium and mesenchyme, until
recently, the primary source of Wnt signaling in the intestine has been unclear. However, new
evidence suggests that mesenchymal Wnts are required both during fetal development and in
adults. It has recently been shown that in embryos, mesenchymal deletion of Wntless, which is
required for the secretion of all Wnts, resulted in a significant decrease in epithelial proliferation
near the time of villus formation, suggesting that mesenchymal Wnt secretion may be required for
epithelial proliferation once villus formation begins (Chin et al., 2016).
Furthermore, the epithelial stem cell niche is likely comprised of Wnt2b- and Wnt5asecreting mesenchymal cells labeled by the forkhead box family member FOXL1, which are
distributed at the interface of the mesenchyme and the epithelium. Diphtheria toxin (DT)-mediated
ablation of FOXL1-expressing cells resulted in the loss of proliferating epithelial cells followed by
a loss of crypt architecture as soon as three days following DT administration (Aoki et al., 2016).
Together, these data show that the maintenance of proliferation in the intestinal epithelium
requires specific Wnt-secreting cells in the mesenchyme.

Inhibition of Wnt signaling by Hedgehog
In addition to promoting epithelial growth, epithelial-mesenchymal communication is required to
limit proliferation. Inappropriate expansion of the proliferative compartment is prevented by bone
morphogenetic protein (BMP) signals in the differentiated cell compartment. In mice with a
conditional deletion of the gene for BMP receptor protein BMPR1A targeted to the intestinal
epithelium, Wnt is de-repressed and the mice develop intestinal polyposis as a result of the
expansion of the stem and progenitor cell populations (He et al., 2004).
Further evidence of the BMP suppression of Wnt signaling was found by investigating the
upstream regulation of BMP by hedgehog (Hh) signaling. The Hh ligands sonic hedgehog (Shh)
and Indian hedgehog (Ihh) are expressed in the epithelium, while their receptors are expressed in
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the mesenchyme. Thus, Hh signaling occurs in a paracrine manner (Kosinski et al., 2010).
Neonatal mice epithelially overexpressing the pan-Hh inhibitor, Hhip, which inhibits both Shh and
Ihh, had hyperproliferative intestinal epithelia, while the villi failed to fully form. Consistent with the
function of BMP as a Wnt inhibitor, the expression of Wnt target genes was upregulated in Hhip
mice (Madison et al., 2005).
Despite previous studies showing that Bmp4 expression is regulated by Shh, deletion of
Shh targeted to the intestinal epithelium did not phenocopy the Hhip mutants. Rather, ablation of
Shh in intestinal epithelium resulted in a decrease in the number of goblet and Paneth cells,
impaired fucosylation of secreted glycoproteins, and ER stress resulting from impaired autophagy
(Gagné-Sansfaçon et al., 2014). Conversely, deletion of Ihh in the intestinal epithelium disrupted
the epithelial-mesenchymal interactions necessary for the regulation of proliferation. The
epithelium of Ihh-mutant intestine was hyperproliferative, with expanded crypts and differentiation
skewed toward a secretory fate. Moreover, whole intestine gene expression analysis by
microarray showed that Ihh mutants had increased expression of Wnt target genes, such as
Sox9, cMyc, and Mmp7, increased expression of the intestinal stem cell marker Lgr5, and a
significant decrease in the expression of BMP signaling genes (Kosinski et al., 2010). Together,
these findings strongly suggest that epithelial Ihh mediates epithelial proliferation by regulating
the mesenchymal expression of BMP ligands. BMP signaling then inhibits Wnt signaling, resulting
in reduced epithelial proliferation.

Cdx1 and Cdx2
During development, the transcription factor caudal-type homeobox 2 (Cdx2) is highly expressed
throughout the intestinal epithelium from the duodenum to the distal colon. While expression of
Cdx2 is primarily restricted to differentiated cells, Cdx1 is expressed throughout the entire
intestinal epithelium, with expression primarily restricted to the crypts, overlapping slightly with
Cdx2 (Silberg et al., 2000).
Perturbation

of

Cdx2

expression

during

embryogenesis

results

in

disrupted

regionalization of the gastrointestinal tract. For example, ectopic expression of CDX2 in the
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murine stomach was sufficient to induce intestinal metaplasia, as was shown by the inappropriate
gastric expression of intestinal epithelial cell markers, including positive staining for intestinal
mucins (Silberg et al., 2002). Notably, in human intestinal metaplastic pyloric mucosa, expression
of gastric transcription factor SOX2 is significantly decreased and expression of CDX1, CDX2,
and the intestinal mucin MUC2 are all increased (Tsukamoto et al., 2004). Thus, CDX2 is capable
of activating the intestinal program in foregut endodermally derived tissue.
Conversely, mice with Cdx2 ablation during early endoderm differentiation developed
gastrointestinal tracts that terminated without a colon and had no opening at the distal end,
resulting in complete intestinal obstruction. Histological examination of the Cdx2-null mutants
revealed that villus development was impaired and that enterocytes failed to develop a brush
border. Thus, though the gut tube retained expression of the pan-endoderm marker FOXA1, the
epithelial cells in the mutant intestine did not become mature differentiated intestinal cells (Gao et
al., 2009).
As opposed to the intestinal metaplasia observed in mice ectopically expressing Cdx2 in
the proximal endoderm, Cdx2-deficient distal endoderm gave rise to tissue that was reminiscent
of mouse esophagus. Not only was the anterior foregut endoderm marker Sox2 inappropriately
expressed in the distal gut, but gene expression profiling of mutant and control E18.5 GI tissue
also showed that the transcriptome of the mutant ileum was more similar to the control
esophagus than to the control ileum. Furthermore, in the mutant ileum, intestine-specific
transcription factor genes, including Hnf4α and Cdx1, were significantly downregulated.
Additionally, the factors Shh, Ihh, were downregulated, while expression of multiple Wnt ligands,
Tcf factors, and Wnt target genes, including cyclin D1 and Sox9, were increased in the mutant
intestine. Together, the altered gene expression indicates that the foregut endoderm
differentiation program was ectopically activated in the distal Cdx2 mutant intestine (Gao et al.,
2009). Thus, CDX2 is the master regulator of the intestinal differentiation program.
In order to better understand the mechanism by which CDX2 regulates gene expression
in the colon, CDX2 chromatin binding was analyzed in Caco2 cells, a line of human epithelial
colorectal adenocarcinoma cells that proliferate rapidly until they reach confluence, at which point
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they develop characteristics of mature enterocytes. These analyses revealed that CDX2 interacts
with multiple different binding partners depending upon the differentiation state of the cells. At
CDX2 binding sites both in proliferating and confluent (i.e. differentiated) Caco2 cells, the FOXA
motif was enriched. However, in pre-confluent (i.e. undifferentiated) Caco2 dividing cells, CDX2
binding sites were enriched for the GATA binding motif and the Wnt-responsive TCF/LEF motifs,
while in differentiated cells, the HNF4A motif was enriched (Verzi et al., 2010). The enrichment of
HNF4A/CDX2 co-occupied sites is consistent with the previous finding that HNF4A controls a
large number of genes required for differentiation of colonic epithelium (Garrison et al., 2006).
Like Cdx2, Hnf4α is also expressed throughout the intestinal epithelium during
development (Garrison et al., 2006). Additionally, chromatin regions that are either co-occupied or
individually occupied by CDX2 and HNF4A are enriched with nucleosomes modified by histone
H3 dimethylated on lysine 4 (H3K4me2), which label active enhancers. While the binding of
HNF4A is dependent on CDX2 binding at normally co-occupied sites, CDX2 binding is unaffected
by Hnf4α ablation. Therefore, although the two transcription factors do not directly interact,
HNF4A likely binds CDX2-occupied sites as a result of CDX2 maintaining a permissive chromatin
structure. CDX1 likely has some functional redundancy with CDX2, as intestine lacking
expression of both Cdx1 and Cdx2 lost more H3K4me2-marked enhancers than were lost in
CDX2-deficient intestine alone. Therefore, CDX factors regulate gene expression by binding at
active enhancers and maintaining an open chromatin conformation (Verzi et al., 2012). Taken
together, these data demonstrate the requirement of CDX-mediated chromatin accessibility for
intestine-specific transcription factors to initiate gene expression and establishes CDX2 as the
master intestinal transcription factor.

Notch signaling
Notch signaling is required in the intestinal epithelium for the fate specification of transit
amplifying cells. Notch signal transduction, which was first studied in Drosophila, is highly
conserved throughout evolution. Mammals have four notch receptors (Notch1-4) and five
canonical ligands: Dll1, Dll3, and Dll4, Jagged1 and Jagged2 (Kopan and Ilagan, 2009). Both
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Notch receptors and their ligands, which are from the DSL (Delta, Serrate, and Lag 2) protein
family, are single-pass transmembrane proteins. Thus, activation of Notch signaling can only take
place between directly apposed cells (Kopan and Ilagan, 2009; Mumm and Kopan, 2000). This
form of cell-cell communication, termed “lateral signaling”, has been suggested to function as an
inhibitor of default cell differentiation, thus allowing neighboring cells to follow secondary fate
pathways.
Upon ligand-mediated Notch activation, the extracellular domain of the Notch receptor,
which binds ligand and inhibits Notch activity in the absence of ligand, is cleaved. Next, the Notch
intracellular domain (NICD) is released from the transmembrane domain by the enzyme γsecretase and transported to the nucleus. In the nucleus, NICD binds the DNA binding protein
RBPJ, converting RBPJ from a repressor to a transcriptional activator. This cascade results in the
transcription of Notch target genes, such as Hes1 (Mumm and Kopan, 2000).
In the intestine, Notch target genes control the switch between an absorptive and a
secretory cell fate. Inhibition of Notch by either the ablation of RBPJ, or by the administration of γsecretase inhibitor, drives cells to a goblet cell fate (van Es et al., 2005). Additionally, deletion of
the transcription factor HES1 in mouse embryos caused a significant increase in the abundance
of cells entering the secretory cell fate (Jensen et al., 2000). Conversely, the constitutive
activation of Notch1 in the intestinal epithelium results in a complete loss of secretory cell
differentiation, while causing the proliferative crypt compartment to expand. This is attributed to
the increased transcriptional repression of the transcription factor MATH1 by HES1 (Fre et al.,
2005).
The requirement of MATH1 for secretory cell differentiation is illustrated by Math1deficient mouse embryos, which completely lack secretory cells (Yang et al., 2001). Lineage
tracing indicates that the differentiated cells expressing MATH1, including goblet, Paneth, and
enteroendocrine, are all from the secretory lineage. Tissue-specific ablation of Math1 in the
intestinal epithelium results in the differentiation of all epithelial cells to absorptive enterocytes.
Furthermore, consistent with the role of secretory cells as initiators of the primary response to
epithelial damage, MATH1-deficient crypts do not increase in proliferation or depth in response to
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small bowel resection. In summary, Notch signaling modulates the abundance of secretory cells
by activating transcription of Hes1, an inhibitor MATH1, a transcription factor required for
secretory cell fate determination (Shroyer et al., 2007).

The FOXA transcription factor family
The forkhead gene family
The winged helix/forkhead box (Fox) transcription factors are a family of proteins that bind DNA
as a monomer and are characterized by a highly conserved 101 amino acid DNA-binding domain,
termed the “winged helix” motif (Clark et al., 1993). Fox genes have been identified in eukaryotes
from yeast (Zhu et al., 1993), nematodes (Kalb et al., 1998), sea anemones (Fritzenwanker et al.,
2004), and zebrafish (Norton et al., 2005) to mice and humans. The mouse genome encodes a
total of 44 Fox genes and the human genome encodes 50 Fox genes, which have been classified
into 19 subfamilies (FOXA-FOXS) (Jackson et al., 2010; Kaestner et al., 2000).
Fork head (fkh), the first member of the Fox family, was identified in Drosophila as a
homeotic regulator of proximal and distal gut tube formation (Weigel et al., 1989). At
approximately the same time, the three mammalian FOXA genes (formerly hepatocyte nuclear
factor 3, HNF3), FOXA1, FOXA2, and FOXA3, were identified as important transcriptional
regulators in rat liver because of their enriched binding to hepatocyte-specific promoters (Lai et
al., 1990). Based on its high degree of amino acid identity (approximately 75%) to the mammalian
FOXA and fkh winged helix domains (Azzaria et al., 1996; Weigel and Jäckle, 1990), in addition
to similar tissue expression to fkh, the C. elegans gene Pha-4 was subsequently identified as an
additional homolog (Kalb et al., 1998). Like fkh in Drosophila, Pha-4 is required for the
development of its digestive organ, the pharynx. Notably, the PHA-4 binding motif TRTTKRY
(Gaudet and Mango, 2002) is nearly identical to the FOXA2 binding motif identified in mouse liver
nuclear lysates (Tuteja et al., 2009). Together, these data point to a highly conserved role for
FOXA homologs throughout evolution in the specification of the gut tube.

Chromatin remodeling
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To investigate the mechanism by which FOXAs regulate gene expression, the DNA-binding
domain of rat FOXA3 and the promoter sequence of the liver gene transthyretin (TTR) were
cocrystallized, thus revealing the butterfly-like “winged helix” three-dimensional structure of FOX
proteins. Additionally, the crystallographic structure showed that there is a high degree of
structural similarity between FOXA3 and linker histone H1 (Clark et al., 1993). A recent
comparison of linker histone H1 deposition in wild type and FOXA1/A2-null (mutant) liver shows
that H1 binding is increased at FOXA1/A2 target regions in mutant liver, while in controls, higher
FOXA2 occupancy is correlated with H1 depletion. Furthermore, binding of liver-specific
transcription factors, such as HNF4A, at FOXA2-bound enhancers was reduced in mutant
hepatocytes (Iwafuchi-Doi et al., 2016). Moreover, it was shown in vitro that by C-terminal
domain-mediated binding of histones H3 and H4, mouse FOXA1 is capable of remodeling
chromatin (Cirillo et al., 2002). Thus, FOXA proteins may maintain an accessible chromatin
conformation for tissue-specific transcription factors by directly interacting with histone proteins.

Tissue expression
Analysis of expression patterns in adult mouse tissues revealed that all three Foxa genes are
highly expressed in the adult liver, stomach, and intestines. However, Foxa1 and Foxa2 are
expressed in the lungs, while Foxa3 is absent. Conversely, Foxa3 alone is highly expressed in
the ovary and testes, heart, thymus, and adipose tissue. Although all three factors are expressed
in the liver, stomach, and intestines, Foxa3 is the most highly expressed (Kaestner et al., 1994).
Despite the similarity in coding sequence between the Foxa genes, with 95% sequence identity
between the Foxa1 and Foxa3 forkhead domains (Clark et al., 1993), differences in regulation
and tissue expression may be explained by the differing sequences of their promoters (Kaestner
et al., 1994). Thus, in some tissues, but not others, ablation of one factor may be compensated
for by upregulation of the one or both of the other factors.
Still, the mechanism by which transcription of the three Foxas is regulated remains
unclear. A FOXA binding site was found upstream of the Foxa1 gene that bound all three FOXAs
in liver nuclear extracts, suggesting autoregulation by FOXA1 and crossregulation by FOXA2 and
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-/-

FOXA3. However, in Foxa1-LacZ homozygous animals (Foxa1 ), in which the fragment of Foxa1
encoding the DNA binding domain was replaced by LacZ, the expression level of the Foxa1-LacZ
allele was the same as for the wild type Foxa1, suggesting FOXA1 does not autoregulate its
expression (Kaestner et al., 1999).

Regulation of tissue specification and organogenesis by FOXA1 and FOXA2
FOXA1 and FOXA2 have both separate and overlapping roles during embryonic development
and in mature tissues. Early in embryogenesis, FOXA2 is required in the visceral endoderm for
proper primitive streak morphogenesis (Dufort et al., 1998), notochord development (Weinstein et
al., 1994) and node formation (Ang and Rossant, 1994). Later, it is required for specification of
the endodermal foregut (Dufort et al., 1998), though not the midgut or hindgut (McKnight et al.,
2010). Organs derived from foregut and midgut endoderm, including the lungs, liver, pancreas,
and intestines, require both FOXA1 and FOXA2 during patterning and in the mature animal.

Lungs: In the embryonic mouse respiratory epithelium, absence of FOXA1 or FOXA2 alone does
not inhibit branching morphogenesis or cell differentiation. However, Foxa1/Foxa2-null lungs,
despite having a normal pulmonary vascular structure, are smaller than control and single mutant
lungs and are lined by immature cuboidal epithelial cells. Furthermore, there is an increase in
Foxa2 mRNA in the Foxa1-mutant respiratory epithelium, while in Foxa2-mutants there is an
increase in Foxa1 mRNA, suggesting that the factors are repressing each other’s expression in
normal lung development. In tissue mosaic for the deletion of Foxa1/Foxa2, absence of
differentiation markers is restricted to the mutant regions. Thus, FOXA1 and FOXA2 have cell
autonomous, overlapping roles in lung morphogenesis (Wan et al., 2005).
Despite the redundancy of FOXA1 and FOXA2 during embryogenesis, postnatal
morphogenesis is significantly altered in Foxa2-null lungs. In addition to increased airspace
enlargement, the Foxa2-mutant respiratory epithelium exhibits goblet cell hyperplasia and
increased macrophage and neutrophil infiltration. Goblet cell hyperplasia in mutant lungs may
result from the de-repression of Mucin5ac (Muc5ac) transcription by FOXA2, as in vitro it was
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shown that FOXA2 directly inhibits MUC5AC expression. Notably, in lung tissue from human
subjects with chronic lung disease, regions of goblet cell hyperplasia lacked FOXA2. Thus,
FOXA2 may be required in the lung for the inhibition of goblet cell differentiation (Wan et al.,
2004).

Liver: The absence of Foxa1, Foxa2, or Foxa3 individually in the endoderm is not sufficient to
prevent liver specification. However, when both Foxa1 and Foxa2 are deleted in the foregut
endoderm of mouse embryos at E8.5, progenitor cells in the foregut endoderm fail to form a liver
bud and the hepatoblast marker alpha-fetoprotein (Afp) is not expressed (Lee et al., 2005).
Ablation of Foxa1 and Foxa2 following liver specification results in hyperproliferation of the biliary
tree from the increased cycling of cholangiocytes as a result of increased signaling by IL-6, an
activator of cholangiocyte proliferation. In control liver, the IL-6 promoter is co-occupied by its
negative regulator, glucocorticoid receptor (GR), and FOXA1/FOXA2. Following deletion of
Foxa1/Foxa2 in the liver, binding at the IL-6 promotor by GR was significantly decreased.
Although the proliferation rate of hepatocytes is unaffected, by three months of age, the bile ducts
of mutant livers become fibrotic. Thus, the FOXA proteins limit bile duct expansion through
regulation of IL-6 expression (Li et al., 2009).

-/-

Pancreas: Although newborn Foxa1 mice are the same weight at birth as their littermates, their
growth lags and they die of severe hypoglycemia by P14. Plasma levels of both insulin and
glucagon, as well as preproglucagon mRNA levels, are reduced in mutants, thus they are unable
to modulate their blood glucose (Kaestner et al., 1999). Like Foxa1

-/-

mice, when deletion of

Foxa2 is targeted to insulin-secreting β-cells by Cre driven by the insulin promoter (InsCre),
Foxa2 mutants die before weaning of hyperinsulinemic hypoglycemia. Unlike Foxa1

-/-

islets,

which have significantly reduced glucose-stimulated insulin secretion (Vatamaniuk et al., 2006),
Foxa2

oxP/loxP

;InsCre islets are hypersensitive to glucose-stimulation, resulting in a significantly

increased ratio of plasma insulin to glucagon, despite the decreased levels of both hormones
compared to controls. An explanation for the abnormal increase in insulin secretion may be that
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FOXA2 targets genes that regulate glucose sensing, as mRNA levels of Kcnj11 and Abcc8, the
genes that encode both subunits of the KATP channel, are significantly downregulated in Foxa2null islets (Sund et al., 2001).
Both FOXA1 and FOXA2 bind a critical enhancer for the transcription factor pancreatic
and duodenal homeobox 1 (Pdx1), which is required for pancreatic development (Lee et al.,
2002). In Foxa1

loxP/loxP

; Foxa2

loxP/loxP

; Pdx1Cre mice, conditional deletion of both Foxa1 and Foxa2

results in mutant mice having severe pancreatic hypoplasia and lacking all Pdx1 expression (Gao
et al., 2008). Pdx1CreERT2-mediated ablation of FOXA1 and FOXA2 in mature islets results in
mice developing severe hypoglycemia. Gene expression array analysis comparing mature
Foxa1

loxP/loxP

; Foxa2

loxP/loxP

; Pdx1CreER and control islets revealed that genes involved in neural

differentiation are upregulated in mutant islets, while factors involved in secretory pathways are
downregulated, such as insulin receptor-related receptor (Insrr) and MLX interacting protein like
(Mlxipl). Significantly, transcription of Mlxipl, which encodes the carbohydrate response elementbinding protein (ChREBP), is directly regulated by FOXA1 and FOXA2, both during development
and in mature islets (Gao et al., 2010). Additionally, in vitro, all three FOXAs are able to
transactivate the preproglucagon promoter (Kaestner et al., 1999). Thus, FOXA proteins are
important factor for the control of glucose homeostasis through the direct regulation of genes that
control glucose sensing and hormone secretion.

Intestines: While Foxa1 is expressed uniformly throughout the epithelium of the developing and
the mature gut, Foxa2 expression is restricted to the intervillus region of perinatal intestines and
to the crypts and goblets cells of the adult intestine. In the murine rectal cancer cell line CMT-93,
which expresses Muc2, Foxa1, and Foxa2, downregulation of Foxa1 and Foxa2 by siRNA
resulted in a dramatic decrease in Muc2 expression. ChIP-PCR confirmed that FOXA1 and
FOXA2 bind to the Muc2 promoter in vivo. Thus, Muc2 is a direct target of FOXA1 and FOXA2
(van der Sluis et al., 2008).
In order to further investigate the role of FOXA1 and FOXA2 in intestinal differentiation,
deletion of Foxa1 and Foxa2 was targeted to the intestinal epithelium by Cre driven by the Villin
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promoter. Although the anterior/posterior patterning of the intestine was normal Foxa1
Foxa2

loxP/loxP

loxP/loxP

;

;VillinCre mice, the number of goblet cells was significantly decreased and mucin

granule density was reduced compared to controls. Notably, Muc2 and Tff3 mRNA levels were
significantly decreased in the colon, but not in the small intestine of mutant mice. However, the
number of chromogranin A-positive enteroendocrine cells was significantly down in the mutant
small intestine (Ye and Kaestner, 2009). Thus, FOXA1 and FOXA2 are not only required for
regulating Muc2 expression, they are also vital for the normal differentiation of intestinal secretory
cells.

Regulation of tissue specification by FOXA3
Although there was initially little evidence for a significant regulatory role for FOXA3, new
functions have recently been discovered. Foxa3-null mouse embryos are morphologically normal
and mice are born healthy and fertile at normal Mendelian ratios. Although Foxa1 and Foxa2
transcript levels are unchanged in mutant stomach and colon, their levels are increased in Foxa3null liver, signifying a possible compensatory increase in transcription. In the mutant liver,
transcription rates for FOXA target genes, including phosphoenolpyruvate carboxykinase (Pck1),
a part of the gluconeogenesis pathway, are reduced, indicating that FOXA3 activates expression
of liver genes (Kaestner et al., 1998). Additionally, FOXA3 may be a significant factor for
promoting liver regeneration following toxic liver injury, as a competitive overexpression screen of
liver genes found that FOXA3 significantly promotes hepatocyte repopulation, while FOXA1 and
FOXA2 do not (Wangensteen et al., 2015). The importance of FOXA3 as a hepatic transcription
factor is underscored by the finding that lentiviral expression of FOXA3, along with HNF1A and
HNF4A, transdifferentiates human fibroblasts to cells that express hepatic gene programs (Huang
et al., 2014).

With their highly conserved overlapping and unique functions, FOXA1, FOXA2, and FOXA3 are
essential for the development and maintenance of tissues derived from the foregut and midgut
endoderm.
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Figure 1.1: Synthesis of the four main mucin type O-glycans. The foundation of mucin protein Olinked glycosylation is the Tn antigen, which is comprised of N-acteylgalactosamine (GalNac)
bound to the -OH group of a serine (Ser) or a threonine (Thr) residue. The Tn antigen is modified
by the addition of galactose and/or N-acetylglucosamine (GlcNAc) to form the four common core
O-glycan structures. Addition of GlcNAc and galactose is carried out by the enzymes listed above
the black arrows. The core structures may then be branched and extended by the addition of
more sugars.
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CHAPTER 2

MATERIALS AND METHODS

Parts of this chapter were adapted from Kieckhaefer et al. 2016. The RNA Polymerase III Subunit
Polr3b is required for the maintenance of small intestinal crypts in mice. Cell Mol Gastroenterol
Hepatol. 2: 783–795.

27

POLR3B MATERIALS AND METHODS:
Derivation of Polr3b

loxP/loxP

;VillinCre mice

The Polr3b conditional mutant allele was derived in mouse embryonic stem cells via
homologous recombination using the targeting construct schematized in Figure 1A. LoxP sites
flanking exon 10 allow for ablation of exon 10 in Polr3b

loxP/loxP

upon Cre activation. The neomycin

cassette was excised by crossing the F1 offspring with Flp1 deleter mice (Rodríguez et al., 2000).
In order to ablate Polr3b conditionally in the intestinal epithelium, Polr3b

loxP/+

mice were crossed

with VillinCre mice, kindly provided to us by Deborah Gumucio (Madison et al., 2002), to obtain
Polr3b

loxP/+

;VillinCre and Polr3b

loxP/loxP

;VillinCre mice. Genotyping was performed by polymerase

chain reaction (PCR) analysis of genomic tail DNA (data not shown). The following primers were
used to detect the Polr3b wild type and mutant allele, yielding a 222 bp product and a 519 bp
product,

respectively:

5’-AGCCTCATTTCTTCGTGGTGA-3’

TGGCCTAGGAAGGGAAGAAAA-3’. Polr3b

loxP/+

;VillinCre and Polr3b

loxP/loxP

and

5’-

mice show no

abnormalities and are viable and fertile. The Cre transgene was detected using: 5’GCGGCATGGTGCAAGTTGAAT-3’ and 5’-CGTTCACCGGCATCAACGTTT-3’ primers (product
size of 232 bp). To perform lineage tracing experiments, Polr3b

loxP/+

;VillinCre and Polr3b

mice were crossed with R26-stop-EYFP mice (B6.129X1-Gt(ROSA)26Sor

loxP/loxP

tm1(EYFP)Cos

/J)

obtained from The Jackson Laboratory (Bar Harbor, ME). All procedures involving mice were
conducted in accordance with approved Institutional Animal Care and Use Committee (IACUC)
protocols.

Laser Capture Microdissection (LCM) and subsequent PCR analysis of wild type and
mutant allele
Paraffin-fixed intestinal tissue was sectioned (5 µm) on nuclease and nucleic acid free
frame slides for laser microdissection (ASEE, FS-LMD-M-50r). Unstained and dehydrated tissue
was air-dried and processed immediately for LCM. Crypt regions were dissected from
Polr3b

loxP/loxP

;VillinCre mice and their wild type littermates into PCR sample tubes for laser

microdissection (ASSEE, ST-LMD-M-500), subsequent overnight proteinase K digestion, and

28

PCR analysis for the presence of the wild type and mutant Polr3b allele using the following
primers:

5’-GACGAATTCCTGCAGCCCAAT-3’

(Polr3bF)

with

5’-

CCCTGGAATGAACAGGGGAAA-3’ (Polr3bR1), which yield a wild type product of 930 bp and a
mutant product of 337 bp. Additional PCR analysis was performed using the same Polr3bF primer
and the Polr3bR2 primer: 5’-GTGGCCGCTTACTGAGATGAA-3’ in order to detect only the wild
type product of 530 bp.

Antibodies
The following antibodies were used for immunofluorescent or immunohistochemical
analysis: rabbit anti-Ki67 (1:1000; Vector Laboratories; Burlingame, CA; VP-K451), rabbit antilysozyme (1:1000; Dako; Glostrup Municipality, Denmark; A0099), mouse anti-E-cadherin (1:500;
BD Transduction Laboratories; San Jose, CA; 610181), rabbit anti-Epcam (1:100; Abcam;
Cambridge, United Kingdom; ab71916), chicken anti-GFP (1:2000; Aves Labs; Tigard, OR; GFP1020), rabbit anti-Sox9 (1:250; Millipore; Billerica, MA; AB5535), rabbit anti-cyclin D1 (1:100;
Biocare Medical; Concord, CA; CRM 307), rabbit anti-cleaved caspase-3 (1:200; Cell Signaling
Technology; Danvers, MA; 9661), and rabbit anti-mucin 2 (1:1000; Santa Cruz Biotechnology;
Dallas, TX; sc-15334). Cy2- and Cy3-conjugated fluorescent secondary antibodies were
purchased from The Jackson Laboratory and used at 1:200 dilution. Biotinylated secondary
antibodies for immunohistochemical assays (Vector Laboratories) were used at a 1:200 dilution
along with the ABC detection system (Vector Laboratories; PK-6100).

Histology, immunohistochemistry and immunofluorescence
Standard Hematoxylin and eosin (H&E) and Alcian blue stains were performed by the
Morphology Core of the Penn Center for Molecular Studies in Digestive and Liver Diseases. For
quantification of Alcian blue stained sections, images of age-matched control and Polr3b-mutant
intestines were analyzed. Positive cells, as well as the total number of epithelial cells, within five
villi per section (from the middle of the crypt base to the middle of the villus tip) were manually
counted in blinded fashion from four control and mutant intestinal sections each. In addition, five
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regions that displayed branching or hyperplasia were counted in P21 mice for total epithelial cells
and Alcian blue-positive cells. The numbers of Alcian blue-positive cells were normalized to total
number of epithelial cells.
TUNEL assay
In order to test the apoptotic cells in the intestinal epithelium, we performed the TUNEL
assay using an in situ cell death detection kit according to the manufacturer’s instructions (Roche
Applied Science; Penzburg, Germany). Cell death was quantified by counting the number of
TUNEL-positive cells per crypt in jejunum sections from P21 mice (control, n = 4 and mutant, n =
4). An average of 20 crypts were counted per animal.

Quantitative PCR analysis
For the analysis of stem cell markers, total RNA was extracted from the jejunal tissue
using the TRIzol reagent method (Invitrogen; Carlsbad, CA; 15596-026). cDNA synthesis and
quantitative PCR analysis were performed as described (Gao et al., 2007). Gene expression was
normalized to mRNA levels of Gapdh. Primer sequences used for the quantitative PCR analysis
have been reported (Foureau et al., 2010; Inoue et al., 2008; Sakamori et al., 2012; Salzman et
al., 2010).
To measure the expression of Pol III targets, total RNA was extracted from the jejunal
tissue of embryonic day 18.5 (E18.5) mice using the mirVana miRNA Isolation Kit (Life
Technologies, AM1560). cDNA synthesis and quantitative PCR analysis were performed using
Custom TaqMan Small RNA Assays (Life Technologies, 4440418) for tRNA-Arg, tRNA-Asn,
tRNA-Cys, tRNA-His, and 5S rRNA. TaqMan MicroRNA Assays (Life Technologies, 4427975)
were used for cDNA synthesis and quantitative PCR analysis of U6 snRNA, snoRNA 202, and
snoRNA 234. Gene expression was normalized to the mean level of snoRNA 202 and snoRNA
234. Primer sequences available on request.
Intestinal crypt/enteroid culture
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Small intestine was harvested from P1 Polr3b-mutant and control mice. After a 30-minute
EDTA (5 mM) incubation, the intestinal crypts were filtered through a 70 μm cell strainer. Crypts
were plated suspended in Matrigel (BD Biosciences, 356231) and cultured in Advanced DMEM/F12 (Thermo Fisher Scientific; Waltham, MA; 12634010) containing the Wnt agonist R-spondin1
(Protein Expression Facility, The Wistar Institute; Philadelphia, PA), murine epidermal growth
factor (mEGF) (Life Technologies; Carlsbad, CA; PMG8043), murine Noggin (mNoggin)
(Peprotech; Rocky Hill, NJ; 250-38), and the Gsk3 inhibitor (CHIR99021) (BioVision; Milpitas, CA;
1677-5) as published (de Lau et al., 2011; Sato et al., 2009). On days 2, 4, and 6, pooled
enteroids were genotyped by qPCR for the presence of the deleted allele using primers Polr3bF
and Polr3bR1, as described above, and undeleted allele using primers Polr3bF2: 5’GCTTGATATCGAATTCCGAAG-3’ and Polr3bR: 5’-CCTCTCTGGAACTCCAACCAA-3’. The
quantity of genomic DNA present in qPCR reactions was normalized to genomic β-actin. In
addition,

proliferation

and

apoptosis

were

assessed

in

developing

enteroids

by

immunofluorescent analysis with Ki67 and cleaved caspase-3, respectively, as described above.

Statistical Analysis
Values represent means ± standard error of the mean for the indicated number of mice
per group. Differences between groups were determined using an unpaired Student's t test (2tailed), with a significance cutoff of p<0.05, unless indicated otherwise. Percentage undeleted
allele quantified in enteroids by qPCR at three different time points (2, 4, and 6 days in culture)
was compared using the Kruskal-Wallis test, followed by Dunn’s Multiple Comparison Test.
Analysis was performed with GraphPad Prism 5 software (GraphPad Software Inc.; La Jolla, CA).

FOXA1/A2 MATERIALS AND METHODS
Derivation of Foxa1

LoxP/LoxP

; Foxa2

LoxP/LoxP

; VillinCre Mice

LoxP

LoxP

The derivation of the Foxa1

, Foxa2

, and VillinCre mice has been described

previously (Ye, 2009). No difference was observed between Foxa1

31

LoxP/+

; Foxa2

LoxP/LoxP

and

Foxa1

LoxP/LoxP

; Foxa2

LoxP/LoxP

mice, hence both genotypes were used as controls and genotyping

was performed as described previously (Ye, 2009).
RNA preparation and quantitative Real-Time PCR (qRT-PCR)
Large intestines were dissected and divided into proximal and distal colon. Total RNA
was extracted using TRIzol (Thermo Fisher Scientific; Waltham, MA) according to the
manufacturer’s protocol. RNA was reverse-transcribed using SuperScriptTM II Reverse
Transcriptase (Thermo Fisher Scientific; Waltham, MA) and quantitative real-time PCR was
performed as described before (control n=3, mutant n=3). (Gupta, 2009).

Immunohistochemistry
Bromodeoxyuridine (BrdU) labeling was performed by intraperitoneal injection of
1ml/100g body weight BrdU solution (catalog no. 00-0103; Thermo Fisher Scientific; Waltham,
MA) 90 minutes prior to dissection. Large intestines were dissected, fixed in 4% PFA overnight,
washed in 1xPBS, and embedded in paraffin. Hematoxylin and eosin staining was performed on
sections of the proximal and distal colon. The following primary antibodies and dilutions were
used for immunostaining: rabbit anti-CD3 1:200 (catalog no. RM-9107; Lab vision; Fremont, CA),
rat anti-CD45R 1:1000 (catalog no. 550786; Pharmingen; San Diego, CA), rat anti-BrdU 1:1000
(catalog no. OBT 0030; Accurate Chemical and Scientific Corp.; Westborg, NY), rabbit antimRELM-β 1:1000 (provided by Dr. Gary Wu—see He et al., 2003). The antibodies were diluted in
PBT (1X PBS with 2% bovine serum albumin and 0.1% Triton X-100). The slides were incubated
with the primary antibody overnight at 4°C, washed in 1X PBS, incubated with biotinylated antigoat, anti-rabbit or anti-rat antibodies, as appropriate, (1:200; Vector Laboratories; Burlingame,
CA) for 30 minutes at 37°C, and then washed in 1X PBS. The slides were incubated with ABC
reagent (VECTASTAIN ABC Kit; Vector Laboratories; Burlingame, CA) for 30 minutes at 37°C,
washed with 1X PBS, and signals developed using the DAB Peroxidase (HRP) Substrate Kit (with
Nickel), 3,3’-diaminobenzidine (Vector Laboratories; Burlingame, CA), before counterstaining of
the sections with hematoxylin. Prism software (GraphPad Software; San Diego, CA, USA) was
used for all statistical analyses of histological experiments.
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Chromatin immunoprecipitation (ChIP), ChIP-sequencing, and analysis
Chromatin preparation and chromatin immunoprecipitation were performed as described
previously (Ye, 2009). Briefly, chromatin was prepared from the isolated colonic crypts of four wild
type C57BL/6 male mice. From each chromatin preparation, two libraries were constructed using
10µg of chromatin and 2µg of anti-rabbit FOXA1 antibody (ab23738; Abcam; Cambridge, United
Kingdom) or 2µg FOXA2 antibody (sc-6554; Santa Cruz Biotechnology; Dallas, TX), respectively.
The

immunoprecipitated

DNA

was

modified

according

to

the

Illumina

protocol

(http://www.illumina.com), subjected to 100-bp sequencing analysis on an Illumina HiSeq 2500
System, and aligned to the mouse genome (mm9).
HOMER software (Heinz, 2010) in ‘factor mode’ was used to call Foxa1 and Foxa2
peaks. Peaks were selected at a false discovery rate (FDR) of 1%, cumulative Poisson p-value of
0.0001, and at least 4-fold greater coverage of reads in the target experiment compared with the
background input reads. A union set of FOXA1 and FOXA2 peaks was constructed using
Bioconductor software’s DiffBind package (Ross-Innes, 2012; Stark, 2011). Regions that were
called in at least two of the eight ChIP samples were selected into the union set.
Genes associated with peaks were identified using GREAT (version 3.0.0) with default
settings (Mclean, 2010). To assess whether DNA-binding sites of other DNA-binding proteins
were enriched in the union set of FOXA1/A2-bound chromatin regions, motif analysis was
performed using MEME-ChIP (version 4.11.1) (Machanick, 2011; Bailey, 2015). The file used for
motif analysis was formatted using the MEME-ChIP workflow on Galaxy (usegalaxy.org)
(Blankenburg, 2010; Giardine, 2005; Goecks, 2010).
The Bioconductor software package ChIPseeker (Yu, 2015) was used to plot the
frequency of Foxa1/A2 target loci within ±3000kb of transcription start sites. To determine the
enrichment of genomic regions bound by FOXA1/A2, ChIPseeker was used to annotate the union
set of FOXA1/A2-bound loci and the background input loci.

RNA-Seq library preparation and analysis
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Total RNA was purified as described above. Libraries were prepared from proximal whole
colons of control (n=3, 14-23 months) and mutant (n=3, 7-18 months) mice. Poly(A) selection was
carried out using the NEBNext Poly(A) mRNA Magnetic Isolation Module (New England Biolabs;
Ipswich, MA). The NEBNext Ultra RNA Library Prep Kit for Illumina was used to complete library
preparation. The libraries were multiplexed and subjected to 100-bp sequencing analysis on an
Illumina HiSeq 2500 System.
Raw sequenced reads were filtered to retain only high quality reads. Ribosomal reads
and repeats were eliminated. Remaining reads were processed with RNA-Seq Unified Mapper
(RUM) (Grant, 2011), which aligns reads to the set of known transcripts included in RefSeq,
UCSC known genes, VEGA transcripts, and the genome, and then outputs feature-level
quantitation (transcript, exon, and intron). To analyze global gene expression profiles, the number
of uniquely aligning read counts to mRNA transcripts in RefSeq and UCSC genes were extracted
from the RUM output. Pairwise comparisons between groups were carried using a custom script
that implemented the Bioconductor software package edgeR (Robinson, 2010) to compute a pvalue and fold-change for each transcript. The p-values were corrected for multiple testing using
the Benjamini & Hochberg mode of the R function p.adjust to compute a false discovery rate
(FDR). The data were summarized for individual genes by selecting a representative transcript
with the highest read counts.
In order to identify physiologically relevant targets of FOXA1/A2, the FOXA1/A2 ChIP-seq
and RNA-seq data were integrated using R (R Core Team, 2016). The probability of the overlap
between differentially expressed genes identified by RNA-seq and peak-associated genes
identified by GREAT was calculated using the hypergeometric distribution function phyper in R.
The disease and functional annotation and prediction upstream regulators of differentially
expressed genes with an FDR < 5% that were also identified as peak-associated genes by
GREAT (above) was performed using QIAGEN's Ingenuity Pathway Analysis
®

(IPA , QIAGEN Redwood City, CA; https://www.qiagenbioinformatics.com/products/ingenuitypathway-analysis/) (Krämer et al., 2014).
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The FOXA1/A2 ChIP-seq data were compared to publicly available colonic epithelial
HNF4A ChIP-seq data (GEO series GSM1266727) (Chahar, 2014). HNF4A peak-associated
genes were identified by GREAT and genes targeted by both FOXA1/A2 and HNF4A were
identified using online Bioinformatics and Research Computing software from the Whitehead
Institute (http://jura.wi.mit.edu/bio/). The probability of the overlap between FOXA1/A2 and
HNF4A target genes using the hypergeometric distribution function phyper in R.
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CHAPTER 3

The RNA Polymerase III Subunit Polr3b is required for the maintenance of small intestinal crypts
in mice.

Parts of this chapter were adapted from Kieckhaefer et al. 2016. The RNA Polymerase III Subunit
Polr3b is required for the maintenance of small intestinal crypts in mice. Cell Mol Gastroenterol
Hepatol. 2: 783–795.
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ABSTRACT
Background & aims: The continuously self-renewing mammalian intestinal epithelium, with high
cellular turnover, depends on adequate protein synthesis for its proliferative capacity. RNA
polymerase III activity is closely related to cellular growth and proliferation. Here, we studied the
role of Polr3b, a large RNA polymerase III subunit, in the mammalian intestinal epithelium.
Methods: We derived mice with an intestinal epithelium-specific hypomorphic mutation of the
Polr3b gene, using VillinCre-mediated gene ablation. Phenotypic consequences of the Polr3b
mutation on the intestinal epithelium in mice were assessed using histological and molecular
methodologies.
Results: The Polr3b mutation severely reduced survival and growth in mice during the first
postnatal week, the period when the expansion of the intestinal epithelium, and thus the
requirement for protein synthesis, are highest. The neonatal intestinal epithelium of
Polr3b

loxP/loxP

;VillinCre mice was characterized by areas with reduced proliferation, abnormal

epithelial architecture, lack of crypts, and impaired Paneth cell differentiation; all accompanied by
reduced Wnt signaling activity in these regions. In addition, enteroids cultured from
Polr3b

loxP/loxP

;VillinCre mice show reduced proliferative activity and increased apoptosis.

Conclusions: We provide evidence for an essential role of the Pol III subunit Polr3b in
orchestrating the establishment of the intestinal epithelium during early postnatal development in
mice.
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INTRODUCTION
The small intestinal epithelium is the fastest self-renewing tissue in mammals, and thus highly
dependent on adequate protein synthesis for proliferation, especially during early postnatal
development, when the expansion of the epithelial layer takes place. In neonatal mice, intervillus
regions of the intestinal epithelium reorganize to give rise to highly proliferative crypt structures,
which increase in number and size during this transition from neonatal to adult function (De Santa
Barbara et al., 2003).
The RNA polymerase III (Pol III) complex transcribes small noncoding RNAs (sncRNAs),
such as transfer RNAs (tRNAs), U6 snRNAs, and 5S ribosomal RNAs (rRNAs) (White, 2008),
which all are involved directly or indirectly in protein synthesis. Studies in Saccharomyces
cerivisiae have shown many factors and mechanisms that regulate Pol III transcription (DumayOdelot et al., 2010). These studies clearly show that high Pol III activity is required during
conditions of rapid growth, whereas reduction in Pol III activity is observed during nutrient
deprivation (Roberts et al., 2003). Although the Pol III complex is highly conserved from yeast to
human beings, unlike in yeast, Pol III targets are repressed differentially in response to nutrient
deprivation in human fibroblasts, indicating that mechanisms of transcriptional regulation of Pol III
genes are more complex in mammals (Orioli et al., 2016).
Although Pol III traditionally has been regarded as functioning in a housekeeping
capacity, studies in metazoans have shown sophisticated mechanisms of transcriptional
regulation of Pol III targets, including cell type–specific transcription of different tRNA genes
(White, 2011). In mammalian cells, numerous studies have pointed to Pol III dysregulation as
playing a role in oncogenic transformation (Grewal, 2014; White, 2011). In support of this finding,
overexpression of Pol III transcripts has been described in multiple cancers and in transformed
cell lines (Chen et al., 1997; Pavon-Eternod et al., 2009; Singh et al., 1985; Winter et al., 2000).
The proto-oncogene proteins mechanistic target of rapamycin complex 1 (mTORC1),
myelocytomatosis oncogene (MYC), p53, and retinoblastoma all directly regulate transcription by
Pol III in human cells (Chesnokov et al., 1996; Gomez-Roman et al., 2003; Michels et al., 2010;
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White et al., 1996). Thus, comprehending the function and regulation of Pol III is vital to the
understanding of tissue growth in health and disease.
Despite the importance of Pol III, little is known about its requirement during
development. In zebrafish, a large-scale mutagenesis screen recovered a mutation, termed slim
jim (slj), that causes an in-frame deletion in the gene encoding the second-largest Pol III subunit,
Polr3b (Yee et al., 2007). The mutation has a profound effect on the proliferation and growth of
intestinal epithelial progenitor cells, consistent with a high demand for protein synthesis in the
rapidly proliferating intestinal epithelium.
The continuously self-renewing mammalian intestinal epithelium, with high cellular
turnover, provides an attractive system to study the role of the Pol III complex in mammalian cell
proliferation. Based on data from previous studies in the slj zebrafish, we hypothesized that
Polr3b might play an important role in the growth and development of the mammalian gut. To
study this hypothesis, we generated a conditional hypomorphic mutation of Polr3b specifically in
the mouse intestinal epithelium.
Here, we show that the disruption of the Pol III complex in the intestinal epithelium by
Polr3b mutation leads to a severe developmental phenotype, mainly characterized by increased
mortality, accompanied by reduced proliferative and differentiation capacity, impaired crypt
maturation, and reduced Wnt signaling in the intestinal epithelium. In summary, our data show the
important role of RNA polymerase III in regulating the establishment of the intestinal epithelium in
mammals.
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RESULTS
Polr3b

loxP/loxP

;VillinCre Mice Have Reduced Survival and Growth

To study the contribution of the RNA polymerase III complex in the intestinal epithelium of
mice, we derived mice with a conditional hypomorphic mutation of the Polr3b gene, which
encodes Polr3b, a major subunit of Pol III (Figure 3.1A). The Polr3b mutation resulted in major
mortality, with only 60% of Polr3b

loxP/loxP

;VillinCre mice (hereafter referred to as Polr3b-mutants)

surviving the first postnatal week (Figure 1B). Surviving mutant mice lagged behind their control
littermates in growth until the third postnatal week (Figure 3.1B and C). Though there was no
difference in intestinal length when normalized to body weight (data not shown), early postnatal
mutant mice were significantly smaller and had shorter intestines than their littermate controls
(Figure 1C–E). As expected, before birth (E18.5), the intestinal tissue of Polr3b

loxP/loxP

;VillinCre

mice already showed a significant reduction in the expression levels of the 5S and U6 RNAs, key
components of the ribosome and splicing machinery, respectively, compared with control
(Polr3b

loxP/loxP

) mice (Figure 3.1F). Milk was present in the stomach of Polr3b-mutant mice from

the first postnatal day until 3 weeks of age (data not shown), suggesting that Polr3b-mutant mice
fed normally.

Newborn Polr3b-Mutant Mice Show Reduced Proliferation and Impaired Crypt Development
Given the slower growth rate of mutant animals and the significant reduction in the
mutant epithelium of RNAs required for translation, we hypothesized that there were defects in
proliferation in the mutant intestine. Therefore, we performed immunostaining for Ki67, a protein
that marks the transit-amplifying cells of the intestinal epithelium. Polr3b

loxP/loxP

;VillinCre intestine

had clear regions lacking Ki67-positive cells at P7, P14, and P21 (Figure 3.2D, F, and H), which
was indicative of reduced proliferative capacity in the intestinal epithelium of young Polr3b-mutant
mice. In addition, P14 mutant intestinal epithelial areas with reduced numbers of Ki67-positive
cells were lacking fully developed crypts, which normally are present by this stage in control mice
(Figure 2E vs F). In regions lacking Ki67, crypts still were not present by P21 in Polr3b-mutant
mice (Figure 2H). At P21, the areas with reduced numbers of Ki67-positive cells were surrounded
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by hyperproliferative regions that had increased numbers of Ki67-positive cells (Figure 3.2H),
suggesting regenerative mechanisms were activated in regions with surviving crypts.

Mutant Mice Develop Abnormal Intestinal Epithelial Architecture
Morphologically, the intestinal epithelium of young Polr3b-mutant mice was affected
severely, showing abnormal crypt and villus architecture (Figure 3.3A). At earlier developmental
stages (E17.5 and P1), no obvious morphologic defects were detected in mutants (data not
shown and Figure 3.3A, respectively). By P7, epithelial defects were present in all regions of the
mutant small intestine and were characterized by an expanded mesenchymal layer, lack of
developing crypts, and branched villus-like structures (Figure 3.3A). At weaning (P21), the
intestinal epithelium of Polr3b-mutant mice continued to show similar morphologic changes to
those seen at P7. In addition, the P21 epithelium contained areas with dramatic hyperplasia
(Figure 3.3A). In contrast to younger animals, a large fraction of the epithelium of adult mutant
mice had normal morphology. However, regions of disorganized epithelium with branched villi
and crypt expansion still were detected in adult Polr3b-mutants (Figure 3.3A).

Undeleted Cre Escaper Cells Proliferate in Hyperplastic Regions of Mutant Intestinal Epithelium
The regenerative response, indicated by the presence of hyperplastic regions and
increased proliferation of the intestinal epithelium seen in P21 Polr3b-mutant mice (Figure 3.3A),
could be explained by stem cells that had escaped Cre-mediated gene ablation. Such incomplete
gene deletion has been reported previously in other studies using the Cre system in the mouse
intestinal epithelium (de Lau et al., 2011). Epithelial stem and transit-amplifying cells that escape
Cre-mediated mutation, and thus have retained normal Polr3b function, would be expected to
have a significant growth advantage over mutant cells.
To assess the presence of undeleted Cre escaper cells in Polr3b-mutant mice in vivo, we
performed laser capture microdissection to dissect crypts from control mice and from hyperplastic
regions in Polr3b-mutant mice (Figure 3.3B). Subsequently, we PCR-amplified the region of the
Polr3b locus encoding the loxP sites to detect undeleted and deleted Polr3b-mutant alleles.
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Indeed, the presence of the undeleted Polr3b allele in the hyperplastic areas of the intestinal
epithelium of Polr3b

loxP/loxP

; VillinCre mice was confirmed by PCR assay using 2 sets of primers

(Figure 3.3C and D). These data indicate the presence of wild-type escaper cells with the
undeleted allele in the Polr3b-mutant intestinal epithelium, which likely were driving the
regenerative response described earlier.
To determine the contribution of apoptosis to the loss of developing crypts in the Pol3bmutant intestinal epithelium, we performed TUNEL assays on P3 (Figure 3.4A and B) and P21
(Figure 3.4C and D) intestines. Because of the mosaicism in Cre activity observed in the mutant
mouse, to distinguish between escaper regions and recombined (mutant) regions in the
epithelium, we crossed our Polr3b

loxP/loxP

;VillinCre mice with R26-stop-EYFP mice. Thus, in

regions where Cre was efficient, the epithelium expressed EYFP as detected by immunostaining
(Figure 3.4A and B). In the control epithelium at P3, no apoptotic cells were detected (Figure
3.4A), while in the mutant epithelium, apoptotic cells were present in EYFP-positive crypts, but
not in EYFP-negative cells (Figure 3.4B). At P21, apoptotic cells were detected in the
mesenchyme, but not the epithelium, of control mice (Figure 3.4C), but apoptotic crypts with
TUNEL-positive cells were detected in the mutant epithelium (Figure 3.4D). A blinded count of the
TUNEL-positive cells per crypt in P21 intestine showed that there were significantly more
apoptotic cells in the mutant intestinal epithelium than in the control epithelium (control, 0.2
TUNEL-positive cells/crypt, N = 4; mutant, 1.2 TUNEL-positive cells/crypt, N = 4; P = .0012)
(Figure 3.4E).

Undeleted Cre Escaper Cell Populations Expand Over Time In Vitro
We hypothesized that if stem cells had escaped Cre-mediated gene ablation, a
progressive increase would result in the proportion of cells carrying the undeleted allele as the
epithelium expands during development. Therefore, to directly measure changes in the
abundance of epithelial cells expressing undeleted Polr3b

loxP/loxP

over time, and without the

potential contamination of mesenchymal cells, we harvested epithelial tissue from newborn
control and Polr3b-mutant mice and cultured it in vitro into enteroids (Figure 3.5; experimental
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scheme shown in Figure3. 5A). Indeed, the fraction of the undeleted allele increased significantly
between days 2 and 6 in culture (P < .05), initially comprising 18% on day 2 in culture, and
increasing to 46% on day 6, as shown by qPCR-based quantification of the undeleted allele
shown in Figure 3.5B.
To determine whether the defects in proliferation observed in vivo in mutant epithelium
persisted when the epithelium was cultured in vitro, we immunostained enteroids for Ki67.
Although all of the control enteroids formed Ki67-positive crypt-like domains (Figure 3.5C),
indicating the presence of stem cells and transit-amplifying cells, mutant enteroids developed into
2 distinctly different structures: enteroids that resembled controls (Figure 3.5D), and enteroids
that formed dilated, cyst-like structures (Figure 3.5E). Although the cyst-like enteroids expressed
Ki67, they failed to form crypt-like domains.
To assess cell death in vitro, after 6 days in culture we stained enteroids for activated
caspase-3 (Figure 3.5F and G). Control enteroids showed no apoptotic cells within the epithelial
layer, caspase-3 staining was present only in dead cells shed into the enteroid lumen (Figure
3.5F). In contrast, as we also observed by TUNEL staining in vivo, Polr3b-deficient enteroids
showed a high frequency of apoptotic cells within the enteroid epithelium itself (Figure 3.5G). This
is consistent with the hypothesis that the intestinal epithelium is being repopulated by cells
expressing the undeleted allele in response to the increased rate of apoptosis in mutant cells.

Over Time, Polr3b

loxP/loxP

;VillinCre Crypts Are Replaced by Highly Proliferative Cre-Escaper Cells

In Vivo
To confirm that the regions of disrupted proliferation observed in Polr3b-mutant intestine
were in tissue where Cre was active, while regions of hyperproliferation were derived from Creescapers,

we

performed

Ki67

EYFP;VillinCre (control) and Polr3b

immunostaining
loxP/loxP

on

epithelia

from

Rosa26-lox-stop-lox-

;Rosa26-lox-stop-lox-EYFP;VillinCre (mutant) P3 mice

(described earlier). As expected, controls uniformly expressed Ki67 at the base of each intervillus
region (Figure 3.6C). In contrast, in regions of mutant epithelium where Cre was active, as
indicated by EYFP staining, very little Ki67 was detected, whereas in EYFP-negative Cre-escaper
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regions, intervillus regions were expanded and contained dense clusters of Ki67-positive cells
(Figure 3.6D, yellow bracket).
The nonproliferative, Ki67-negative regions interspersed with hyperproliferative crypts
observed in the Polr3b-mutant small intestine resemble small intestinal epithelium that
regenerates after exposure to ionizing radiation. The regenerative response in injured intestine is
driven by Wnt signaling (Clevers et al., 2014). Indeed, even in irradiated crypts in which Lgr5

+

stem cells have been ablated, constitutive activation of Wnt by ablation of Apc is sufficient to drive
crypt hyperplasia (Metcalfe et al., 2014). Therefore, to determine whether Wnt pathway activation
contributed to proliferation in escaper regions of Polr3b-deficient gut, we performed
immunostaining for the Wnt target cyclin D1.
At P3, immunohistochemical staining showed that in controls, cyclin D1 was expressed
uniformly in the intervillus regions (Figure 3.6E), whereas mutant regions (EYFP-positive regions)
of the Polr3b-mutant epithelium lacked cyclin D1-positive cells (Figure 3.6F). In contrast, EYFPnegative regions of the P3 Polr3b-mutant epithelium (highlighted by a yellow bracket), showed
dense clusters of cyclin D1-positive cells (Figure 3.6F). Lack of active Wnt signaling in the Polr3bdeficient small intestine was confirmed by staining for b-catenin. As shown in Figure 3.6G, in
control tissue, intervillus regions show strong cytoplasmic and nuclear b-catenin staining,
indicative of Wnt pathway activation. In striking contrast, most of the P3 Polr3b-mutant epithelium
is b-catenin negative, with the exception of an area of regenerative epithelium bracketed in yellow
(Figure 3.6H).
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DISCUSSION
Previous studies in yeast and zebrafish have shown the importance of the RNA Pol III
complex in cell growth and tissue development. More specifically, the zebrafish mutant slj, with a
mutation in the second largest Pol III subunit Polr3b, causes defects in digestive tract
development.16 Here, we present a model to study the role of Pol III in mammalian intestinal
epithelial development and proliferation. We show that decreased activity of the Pol III complex in
the mouse intestinal epithelium leads to increased mortality of Polr3b-mutant mice in the first
postnatal week. Surviving Polr3b-mutant mice show reduced proliferation, impaired crypt
development, and loss of active Wnt signaling. This initial phenotype is followed by a regenerative
response around weaning, which is driven by cells that escape Cre-mediated mutation (Figure
3.7A). Because of the diminished Pol III activity caused by the Polr3b mutation, and resulting low
levels of 5S rRNA and U6 snRNA, the high demand for protein synthesis during early intestinal
epithelial tissue expansion cannot be met. These events result in impaired crypt development and
increased apoptosis in crypts. These data show the important role of Polr3b and the Pol III
complex in the establishment of the intestinal epithelium during early postnatal life in mammals
(Figure 3.7B). The conditional hypomorphic Polr3b-mutant mice described earlier will allow a
detailed investigation of the contribution of RNA polymerase III in all tissue and cell types for
which a Cre line is available.
The epithelium of the small intestine is the most rapidly self-renewing mammalian tissue,
and thus it is required to be capable of modulating protein synthesis in response to environmental
stress or during tissue expansion/growth. During periods of starvation, the gut responds by
decreasing villus size, crypt size, and the rate of cell cycling (Altmann, 1972). Protein malnutrition
alone also results in histologic abnormalities, such as villi fused at the base accompanied by villus
blunting, or even the absence of villus architecture (Tandon et al., 1968). The Pol III complex
plays an essential role in protein synthesis in all eukaryotic cells (White, 2004). Therefore,
sufficient Pol III activity is predicted to be essential for intestinal epithelial function and survival.
The simplest explanation of the disrupted development of the small intestine of Polr3b
mutants is that the reduced Pol III activity impairs cell proliferation because the high metabolic
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demands of the epithelium cannot be met. Indeed, the mutant intestine shows several similarities
to both fasted and protein-starved small intestines: a decrease in cycling cells, abnormal
branched villus architecture, and increased apoptosis in epithelial cells (Altmann, 1972; Boza et
al., 1999; Tandon et al., 1968; White, 2004). The Polr3b mutant intestine thus mimics the
malnourished state because the levels of 5S rRNA and U6 snRNA, which are required for protein
synthesis, are decreased as a result of low Pol III activity. Defects in protein production
machinery thus have a phenotype reminiscent of amino acid deficiency, because in both cases
the high demand for protein synthesis during early intestinal epithelial tissue expansion cannot be
met.
Yeast and zebrafish studies have suggested that the structural effects of Polr3b
mutations resulting in impaired transcription by Pol III are caused by the destabilization of the
interaction between the Polr3b protein and another Pol III subunit, Polr3k (Landrieux et al., 2006;
Yee et al., 2007). The yeast homolog of Polr3k is required for Pol III to efficiently perform multiple
rounds of transcription on the same gene, which determines the overall output of the complex
(Flores et al., 1999). Thus, the Polr3b mutation in mice results in a reduction in the overall
abundance of Pol III transcripts, but without a complete loss of transcription by Pol III, as also was
evident by the reduction, but not elimination, of Pol III transcripts in the mutant intestine we
documented in Figure 1.
Not surprisingly, rapidly dividing cancer cells have an extremely high demand for protein
synthesis, and tRNA abundance is increased in many cancers such as multiple myeloma and
breast cancer (Pavon-Eternod et al., 2009; Zhou et al., 2009). Multiple oncogenic (extracellular
signal-regulated kinase (ERK), TORC1, and MYC) and tumor suppressor (p53, MAF1,
retinoblastoma) pathways regulate RNA polymerase III activity and thus tRNA abundance
(reviewed by (White, 2008) and (Grewal, 2014)). Given the development of small-molecule
inhibitors of RNA polymerase III, reducing tRNA abundance has been suggested as a novel
targeted approach for cancer therapy. Indeed, in a recent report, Yee et al. used the RNA
polymerase III inhibitor ML-60218 developed by Wu et al., 2003 in combination with the histone
deacetylase inhibitor suberoylanilide hydroxamic acid to reduce proliferation in two human

46

pancreatic adenocarcinoma cell lines (Yee et al., 2012). As noted by the investigators, the safety
of ML-60218 in human beings has not yet been evaluated. Given the striking dependency of the
mammalian intestinal epithelium on normal rates of RNA polymerase III we showed earlier, it is
questionable if globally acting, small-molecule inhibitors of this enzyme can be developed into
successful drugs to treat cancer.
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FIGURES
Figure 3.1

Figure 3.1: The Polr3b mutation in mice leads to reduced survival, delayed growth, and
decreased intestinal epithelial transcription of snRNAs. (A) Targeting strategy employed for
conditional ablation of exon 10 (E10) of the Polr3b gene. After germ line transmission, the FRTflanked neomycin resistance gene (PGK-Neo cassette) was excised by crossing to Flp deleter
mice (Flp). Polr3b

loxP/loxP

;VillinCre mice were derived by intercrossing Polr3b

LoxP/+

with VillinCre

mice. (B) Kaplan-Meier survival curve of control and mutant mice during the first eight postnatal
days, showing a significantly lower survival rate in Polr3b-mutant mice compared to littermate
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controls (Log-rank (Mantel-Cox) and Gehan-Breslow-Wilcoxon Test; p<0.0001, n=12-28). (C)
Significantly reduced body weight during the pre-weaning period in Polr3b-mutant mice (mean ±
SEM; *p<0.05; n=3-47). During weaning, when the regenerative response is observed, Polr3bmutant mice start to catch up in body weight with their littermate controls. (D) Polr3b-mutant mice
(right) are visibly smaller than their control littermates (left), at P3. (E) P1 control and mutant
stomach, large intestine, and colon. (F) Real-time qPCR analysis of expression of tRNA-Arg,
tRNA-Asn, tRNA-Cys, tRNA-His, 5S rRNA, and U6 snRNA in E18.5 control (n=7) and mutant
(n=10) mice (mean ± SEM; *p= 0.0496, Student’s t-test, **p=0.002, Mann Whitney test). Data
were normalized to the mean of snoRNA 202 and snoRNA 234.
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Figure 3.2

Figure 3.2: Proliferation is reduced in neonatal Polr3b
sporadic

hyperplasia

and

enhanced

loxP/loxP

proliferative

;VillinCre small intestine, followed by
activity

during

weaning.

Ki67

immunohistochemistry of control and Polr3b-mutant mice at P1 (A and B), P7 (C and D), P14 (E
and F), and P21 (G and H). At all stages, Polr3b-mutant mice show jejunal regions lacking Ki67positive cells (indicated by arrows). At P21, the epithelium of Polr3b-mutant mice displays
hyperproliferative regions with expanded crypts and an increased number of Ki67-positive cells.
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Figure 3.3

Figure 3.3: Hyperplastic regions of the Polr3b-mutant intestinal epithelium at P21 contain wild
type ‘Cre-escaper’ cells with the undeleted Polr3b allele. (A) H&E staining of the intestinal
epithelium showing the morphology of the jejunal epithelium of control and mutant mice at P1
(20X magnification), P7 (10X magnification), P21 (20X magnification), and adult stage (20X
magnification). Areas with expanded mesenchyme, villus branching, and lack of developing
crypts are present in P7 Polr3b-mutant epithelium (yellow box). At P21, hyperplastic areas are
clearly visible in mutant mice (yellow box). In adults, the intestinal epithelium of Polr3b-mutant
mice shows improved morphology; however, areas with villus branching are still detected (yellow
box). (B) Representative pictures before and after laser capture microdissection (LCM) of normal
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crypts dissected from control and hyperplastic regions from P21 mutant mice. (C) Scheme of
primer design and PCR product size for amplification using different primer sets for LCM-PCR
analysis. Primers F and R1 were designed surrounding the loxP sites flanking exon 10 of the
Polr3b gene resulting in the amplification of the longer, undeleted Polr3b PCR product (1,018 bp)
or the shorter, mutant Polr3b gene PCR product (337 bp). An additional reverse primer (R2) was
designed within the loxP-flanked region of the Polr3b gene, which when used with the forward (F)
primer, results in the amplification of the undeleted Pol3b PCR product only (530 bp). (D) PCR
results for LCM-dissected regions from control crypts (control) and Polr3b-mutant crypts from
hyperplastic regions (mutant HR), showing the presence of the undeleted Polr3b allele in control
crypts, and both deleted as well as undeleted alleles in Polr3b-mutant crypts from hyperplastic
regions using both primer combinations (F+R1 and F+R2).
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Figure 3.4

Figure 3.4: The Polr3b mutation is associated with crypt cell death. Apoptotic cells (red) in the
crypts were analyzed by performing the TUNEL assay on intestinal epithelial tissue at P3 (A and
B) and P21 (weaning) (C and D). (A and B) Green staining represents YFP, which is visible only
in Cre-expressing tissue. Red = TUNEL, white = E-cadherin, and blue = DAPI. For increased
clarity, the inset in B, which is a 3x enlargement of the dying crypt indicated by the yellow arrow,
shows only YFP and TUNEL staining. (C and D) Green = E-cadherin, red = TUNEL, and blue =
DAPI. During weaning (P21), TUNEL-positive crypts were still not detected in control tissue (C),
but were seen in mutant animals (D). The inset in D is a 2x enlargement of the dying crypt
indicated by the yellow arrow. No TUNEL-positive cells were detected in crypts of control mice (A
and C), though apoptotic cells were detected in the mesenchyme. Crypt epithelial cells positive
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for TUNEL staining were present in Polr3b-mutant intestinal epithelium in neonates and during
weaning (B and D). TUNEL-positive epithelial cells were only present in the tissue where cre was
active in mutant animals (B). (E) Apoptosis is significantly increased in mutant epithelium at P21.
Cell death was quantified by counting the number of TUNEL-positive cells per crypt in jejunum
sections from P21 mice (control, n = 4; mutant, n = 4; *p = 0.0012, Student’s t-test).
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Figure 3.5

Figure 3.5: Increased cell death is accompanied by expansion of ‘Cre-escaper’ cells in mutant
epithelium in vitro. (A and B) Cleaved caspase 3 (red) staining of enteroids from P1 gut on day 6
in culture (blue = DAPI). Increased cell death was detected in Polr3b-mutant enteroids compared
to controls. In control enteroids (A), cell death was detected only in cells shed into the lumen,
while in mutant enteroids (B), cell death was also seen in peripheral cells (yellow arrows). Images
are at 40x magnification. Scale bar = 500 μM. (C, D, and F) Ki67 staining of enteroids from P1 gut
on day 4 in culture. Mutant enteroids developed into two distinctly different structures: enteroids
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with Ki67 expression at the tips of crypt-like buds (F), resembling controls (C), and dilated, cystlike structures with patches of Ki67 expression surrounded by flattened Ki67-negative cells (D).
(E) Scheme for the culture and harvesting of P1 intestinal enteroids. (F) Quantification of
undeleted Polr3b exon 10 in genomic DNA from enteroids after 2, 4, and 6 days in culture, as
shown in (E) (Error bars indicate SEM; *p < 0.05, paired, one-tailed Student’s t-test; control, n=5;
mutants, n=6).
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Figure 3.6

Figure 3.6:

Hyperproliferative

Cre-escaper

cells

repopulate

the Polr3b-mutant

epithelium. Rosa26-lox-stop-lox-YFP mice were crossed with Polr3b

LoxP/LoxP

intestinal

;VillinCre mice to

show which sections of the tissue are Polr3b mutant (YFP-positive), and which are Polr3b wildtype Cre-escaper cells (YFP-negative). (A and B) Red, E-cadherin; green, EYFP; and blue, 4′,6diamidino-2-phenylindole.
(B) Polr3b

LoxP/LoxP

(A) Rosa26-lox-stop-lox-YFP;VillinCre (control)

; Rosa26-lox-stop-lox-YFP;VillinCre (mutant)

jejunum.

jejunum.
The yellow

bracket indicates a Cre-escaper region that is negative for YFP. (C and D) Red, Ki67; green,
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EYFP; and blue, 4′,6-diamidino-2-phenylindole. (D) Crypts in the Cre-escaper region (yellow
bracket) of the mutant intestine have (C) a higher density of Ki67-positive cells than crypts in the
control intestine. (D) Almost no Ki67 was visible in Polr3b mutant tissue outside the bracketed
area. (E and F) Red, cyclin D1; green, EYFP; and blue, 4′,6-diamidino-2-phenylindole. (F)
In Polr3b-mutant mice, expression of the Wnt target protein cyclin D1 is reduced in mutant tissue
compared with the (E) control intestine, whereas escaper regions have dramatically increased
cyclin D1 staining (yellow bracket). (G and H) Brown, β-catenin; red, nuclear fast red
counterstain.
(H) Polr3b

LoxP/LoxP

(G) Rosa26-lox-stop-lox-YFP;VillinCre (control)
; Rosa26-lox-stop-lox-YFP;VillinCre (mutant)

jejunum.

jejunum.
The yellow

bracket indicates a Cre-escaper region that has active Wnt signaling, as indicated by nuclear βcatenin staining.
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Figure 3.7

Figure 3.7: Summary of the effects of the Polr3b mutation on the mouse intestinal epithelial
development and maintenance. (A) Right after birth, large areas lacking proliferative capacity are
present (Newborn (P3)). During weaning (P21), regions lacking proliferative capacity are present
with very low or absent Wnt-pathway activity, consistent with affected crypt architecture. By P21
the affected regions in the Polr3b-mutant epithelium are surrounded by hyperplastic regions,
which are most likely initiated by the wild type ‘escaper’ stem cells that have escaped Crerecombination of the Polr3b gene. These regions are repopulating the intestinal epithelium,
resulting in normalization of epithelial morphology in Polr3b-mutant intestinal epithelium in adults.
(B) The mutation in Polr3b leads to reduced Pol III activity, which leads to reduced transcription of
small noncoding RNAs required for translation results in increased crypt death, reduced Wnt
signaling, decreased proliferative activity, impaired crypt maturation, and altered epithelial
architecture in mutant tissue. The increased death of mutant cells creates a selective advantage
for Cre-escaper cells in the intestinal epithelium of Polr3b-mutant mice.
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CHAPTER 4
The FOXA Transcription Factors Sustain Murine Intestinal Health by Regulating Crohn’s Disease
Risk Loci
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ABSTRACT
While the primary cause of intestinal inflammation in IBD is thought to be an inappropriate
immune response to lumenal antigens, genome-wide association studies (GWAS) have also
implicated multiple genetic loci associated with genes expressed in the intestinal epithelium itself.
Defects in the mucus layer, which is required for limiting the exposure of epithelial cells to
pathogens, result in inflammation. It was previously shown that mucin expression is altered and
Mucin2 (Muc2), the main component of intestinal mucus, is downregulated by deletion of the
paralogous transcription factors FOXA1 and FOXA2 in the mouse intestinal epithelium. Mice
deficient in Muc2 develop intestinal inflammation and colorectal cancer, suggesting a potential
role for the FOXA factors in the maintenance of an intact mucus layer and intestinal epithelial
health. To investigate the requirement of Foxa1/a2 in the maintenance of intestinal barrier
function, I analyzed immune cell infiltration into the epithelium of the Foxa1/a2-deficient colon in
mice of advanced age (>7 months). Immunohistochemical staining showed that the Foxa1/a2deficient colonic epithelium displays increased susceptibility to spontaneous colitis. To analyze
the mechanism of increased susceptibility to colitis in Foxa1/a2 mutants, I performed FOXA1 and
FOXA2 chromatin immunoprecipitation assays followed by ultra-high throughput sequencing
(ChIP-Seq) analysis on wild type mouse colonic crypts followed by RNA-seq on Foxa1/a2deficient and control aged colon to identify relevant FOXA targets. Significantly enriched
FOXA1/A2 binding sites were identified in close proximity to the IBD risk gene Fut2, which was
downregulated in mutant colon. Additionally, FOXA1/A2 binding sites were found upstream of the
glycosyltransferase genes B3gnt6 and Gcnt3 and downstream of the gene for the secreted
immune effector RELM-β. These findings suggest that FOXA factors regulate modulators of
barrier function and that downregulation of these genes may contribute to IBD pathogenesis.
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INTRODUCTION
Inflammatory bowel disease (IBD), which includes Crohn’s disease (CD) and ulcerative
colitis (UC), currently affects 3.1 million people in the US (Dahlhamer et al., 2016). Genetic
causes play an important role in the pathogenesis of IBD (Abraham and Cho, 2009), but
inheritance does not follow simple Mendelian laws, suggesting that multiple genetic factors and
environmental triggers are involved. Genome-wide association studies (GWAS) have identified
single-nucleotide polymorphisms associated with increased susceptibility to IBD (Franke et al.,
2010; Jostins et al., 2012; Liu et al., 2015). Among these loci are the epithelially-expressed genes
‘autophagy-related, 16-like’ (ATG16L1), ‘nucleotide-binding oligomerization domain 2’ (NOD2),
and ‘immunity-related GTPase’ (IRGM), all part of the autophagosome pathway (Rioux et al.,
2007). Autophagy is responsible for the degradation of cellular constituents and the digestion of
pathogens (“xenophagy”), including bacteria, viruses, and parasites, and the activation of the
innate and adaptive immunity pathways (Levine and Deretic, 2007).
An important barrier between the gut epithelium and lumenal pathogens is the protective
mucus layer on the apical surface of the intestinal epithelium. Notably, MUC19, a member of the
gel-forming mucin protein family, was identified as a potential IBD risk gene (Franke et al., 2010).
This reinforces the notion that in addition to autophagy, mucus, which is produced and secreted
by epithelial goblet cells and which limits exposure of epithelial cells to pathogens, is vital for
maintaining intestinal health. Consequently, the association of these intestinal epithelial genes
with human IBD emphasizes that physiological adaptive and innate immune responses, as well
as an intact intestinal epithelial cell and mucus layer, are critical for the manifestation of IBD.
As previously shown, mucus-secreting goblet cell differentiation and Mucin2 (Muc2)
transcription are regulated by the winged-helix transcription factors FOXA1 and FOXA2 (Ye and
Kaestner, 2009). Deletion of Foxa1 and Foxa2 in the mouse intestinal epithelium impairs
secretory cell differentiation, and results in altered mucin expression, including Muc2
downregulation. Interestingly, the Muc2 gene is a direct FOXA1/A2 target (van der Sluis et al.,
-/-

2008; Ye and Kaestner, 2009) and Muc2-deficient mice (Muc2 ) develop intestinal inflammation
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and colorectal cancer (Van der Sluis et al., 2006; Velcich, 2002), suggesting a potential role for
the FOXA factors in the maintenance of an intact mucus layer and intestinal epithelial health.
Here, I show that simultaneous deletion of Foxa1 and Foxa2 in the gastrointestinal
epithelium of mice leads to increased susceptibility to spontaneous colitis. FOXA1 and FOXA2
chromatin immunoprecipitation followed by ultra-high throughput sequencing (ChIP-Seq analysis)
of the colon revealed FOXA1 and FOXA2 binding sites associated with multiple genes that
influence intestinal health, including the ortholog of the human IBD-associated gene
‘fucosyltransferase 2’ (Fut2). The predisposition to colitis in Foxa1/Foxa2-deficient mice and the
regulatory role of FOXA factors in human IBD-associated genes suggest that additional FOXAregulated factors may contribute to human IBD pathogenesis.
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RESULTS
Aged Foxa1/a2 mutant mice spontaneously develop colitis-like features.
While examining mice deficient for Foxa1/a2 in the intestinal epithelium (Foxa1
Foxa2

LoxP/LoxP

LoxP/LoxP

,

VillinCre) (Ye, 2009), I noticed that aged mutant mice spontaneously develop

several features of colitis. Upon dissection, I observed a distended and fragile colon in Foxa1/a2
mutants.
To determine whether the altered morphology of Foxa1/a2-deficient colon was caused by
inflammation, I stained for CD45R, a B-lymphocyte marker, and CD3, a T-lymphocyte marker
+

(Figure 4.1B and C, respectively). The dramatically increased number of CD45R lymphoid
nodules in aged Foxa1/a2 mutants compared to controls demonstrates that spontaneous
inflammation is increased in the aged mutant colonic epithelium. This finding was accompanied
by a large increase in the number of T-lymphocytes in the lamina propria.
Using a defined set of criteria (Kim et al., 2012), blinded assessment by a veterinary
pathologist of colon sections stained with hematoxylin and eosin confirmed my observations of
the spontaneous colitis phenotype. Although 8-week-old mutants did not have significantly
increased damage scores, the assessment revealed that the aged mutant colonic epithelium
displayed distorted crypt architecture, increased immune cell infiltration, crypt abscesses, and
goblet cell depletion, resulting in significantly increased total histological damage scores when
compared to aged littermate controls (Figure 4.1A and 1D).
Alcian blue staining of mucopolysaccharides highlighted the altered goblet cell
morphology in Foxa1/a2-deficient colons. The goblet cells in aged mutants displayed smaller and
fewer mucin granules than age-matched controls (Figure 4.2A), consistent with the previous
observations in the small intestine (Ye and Kaestner, 2009) and histological features of IBD
(Baumgart and Sandborn, 2012; Danese and Fiocchi, 2011). In addition, by measuring BrdU
incorporation into epithelial cells in S-phase of the cell cycle, I observed a significant increase in
epithelial proliferation in the Foxa1/a2-deficient colon, which is reminiscent of observations made
-/-

previously in the Muc2 colon (Van der Sluis et al., 2006; Velcich, 2002) (Figure 4.2B and 2C).

64

FOXA1 and FOXA2 bind genes orthologous to IBD risk loci in colonic crypt epithelium.
To elucidate the molecular mechanisms underlying the spontaneous colitis in aged
Foxa1/a2 mutants, I performed FOXA1 and FOXA2 ChIP-seq analysis on purified crypts from
wild type mouse colon to identify relevant FOXA targets. Due to the high percentage of sequence
identity between the two target proteins, especially in the DNA binding domains (Clark, 1993), I
first validated that the antibodies I used to immunoprecipitate FOXA1 and FOXA2 were
monospecific and performed ChIP-qPCR for the known FOXA liver target Cdx2. At the Cdx2
enhancer in Foxa1-null liver lysates, binding by the antibody against FOXA1 was depleted (Figure
4.3A). Likewise, binding by the antibody against FOXA2 was depleted in Foxa2-null liver lysates
(Figure 4.3B). Thus, the two antibodies specifically bind their respective target proteins.
An important question in transcriptional regulation by paralogous DNA binding proteins
such as FOXA1 and FOXA2 is whether they occupy the same, overlapping, or distinct binding
sites in chromatin. Early work measuring the in vitro in DNA binding affinities had suggested
distinct preferences for DNA sequence motifs for FOXA1 and FOXA2, then known as Hnf3α and
Hnf3β, respectively (Lai et al., 1990). In addition, ChIP-seq experiments on murine liver had
found partially overlapping target sets for FOXA1 and FOXA2 with hundreds of genes uniquely
bound by FOXA1 (Bochkis et al., 2012).
Therefore, I compared the two FOXA cistromes by plotting the normalized reads per
million values (RPM) for each peak called by HOMER in the union of the FOXA1 and the FOXA2
ChIP-seq datasets (Figure 4.4A). Linear regression of the plotted points in Figure 4.4A indicates
the overall binding strength of Foxa2 is marginally stronger than that of Foxa1 (y = 0.27 + 1.1x, r

2

= 0.828). Remarkably, the plot shows that the two FOXA factors have the same relative binding
frequency at thousands of target loci. Thus, in colonic crypts FOXA1 and FOXA2 bind to the
same set of target genes in colonic crypts, providing a molecular explanation for the lack of
intestinal phenotypes in the single gene conditional gene ablation models (Ye and Kaestner,
2009).
Motif analysis of the union FOXA1/A2 ChIP data by MEME-ChIP identified a de novo
binding motif (E = 2.2x10

-638

) that is nearly identical to both the previously published FOXA1 and
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-9

-16

the FOXA2 canonical binding motifs (FOXA1, p = 2.32x10 ; FOXA2, p = 1.71x10 ) (Figure
4.4B) (Tuteja et al., 2009; Zhang et al., 2008). Therefore, the regions identified by FOXA1/A2
binding in my ChIP-seq data represent cis-regulatory sites in the colonic epithelium.
The binding of FOXA1/A2 in colonic crypts is enriched for sites close to transcriptional
start sites (Figures 4.4C and D), which suggests that FOXA factors regulate transcription by
binding both enhancers and promoters. Analysis of the genomic binding distribution of
FOXA1/A2-bound regions (Figure 4.4D) shows that there is an enrichment of FOXA binding in
promoter regions relative to the frequency of promoters in the genome. This is in contrast to the
liver, where FOXA binding occurs predominantly at distal enhancers (Bochkis et al., 2012).
In addition to the enriched FOXA motif identified in the union dataset, analysis of
sequences within the FOXA-bound regions also identified significant enrichment of an HNF4A-6

like motif (p = 2.45x10 ) (Figure 4.4E). Intersection of FOXA1/A2 and HNF4A (Chahar et al.,
2014) target genes in the colonic epithelium revealed a significant overlap (Figures 4.4F, 4.5, and
4.6A). Regulatory regions co-occupied by FOXA2 and HNF4A have previously been identified in
the fetal and the mature liver (Alder et al., 2014). These data support the idea that FOXA1/A2 and
HNF4A also co-regulate of a set of target genes in the colon.

FOXA targets in the colon regulate barrier function and inflammatory response
To identify physiologically relevant targets of FOXA in the colonic epithelium, I performed
transcriptomic analysis of control and Foxa1/a2-deficient colon. Integration of these data with my
ChIP-seq results revealed 86 genes that were both differentially expressed (FDR < 0.05) and also
bound by FOXA1/A2 (Table 4.1). Of these genes, 67 were also bound by HNF4A, including
Muc2, Fut2, B3gnt6, Gcnt3, and Tlr1 (discussed below). In addition to identifying an enrichment
of genes associated with different types of epithelial cancer, functional and disease annotation by
Ingenuity Pathway Analysis (Krämer et al., 2014) (Table 4.2) of differentially expressed,
FOXA1/A2-bound genes identified an enrichment of genes involved in maintaining the
morphology of the mucosa, as well as genes associated with the inflammatory response. Within
the subset of mucosa-associated genes, I identified the gene for the main component of intestinal
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mucus, Muc2. Consistent with the direct binding by FOXA1/A2 to the Muc2 promoter in vitro (van
der Sluis et al., 2008), I observed not only that FOXA1/A2 binds the Muc2 promoter in vivo, but
also that in the Foxa1/a2-null colon Muc2 steady state transcription levels are significantly
decreased (Figure 4.5A and B).
Notably, genes required for post-translational glycosylation of MUC2, including Fut2,
‘glucosaminyl (N-acetyl) transferase 3, mucin type’ (Gcnt3), and the gene for the upstream
enzyme of GCNT3, ‘UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 6’ (B3gnt6),
are also downregulated FOXA1/A2 targets (Figure 4.5C-D). While B3GNT6 and GCNT3 are
required for the enzymatic addition of O-type glycans to mucin proteins (Figure 1.1), which form
the core structures of the extensive carbohydrate branches of MUC2 (Honke and Taniguchi,
2002; Iwai et al., 2002), the FUT2 enzyme is responsible for further modifying glycosylated
proteins on the mucosa and in bodily secretions (Becker and Lowe, 2003). The heavily
glycosylated MUC2 protein constitutes the main barrier in the colon between the epithelium and
commensal gut bacteria (Bergstrom and Xia, 2013).
In concert with mucus barrier genes, the transcription of FOXA1/A2 target genes involved
in host defense against bacteria is also significantly reduced in Foxa1/a2 mutants. The most
downregulated gene is defensin alpha 6 (Defa6) (Table 4.1), which encodes a secreted
antimicrobial peptide (Jarczak et al., 2013). Regulators of intestinal inflammation, including Tolllike receptor 1 (Tlr1) and Resistin-like b (Retnlb or Relm-b), are also FOXA1/A2 targets with
reduced expression in mutants (Figure 4.6). The pattern recognition receptor TLR1
heterodimerizes with TLR2 to detect bacterial lipopeptides and initiate and immune response
(Farhat et al., 2008). RELM-b is secreted by goblet cells in the colon in response to bacterial
colonization (He et al., 2003) and is protective against TNBS-induced inflammation (Krimi et al.,
2008; Steppan et al., 2001). In addition to significantly decreased levels of Tlr1 and Relm-b
mRNA (Figure 4.6A-D), goblet cell RELM-b protein is also considerably depleted in FOXA1/A2
deficient colon of aged mice (Figure 4.6E).
Prediction of control nodes for differentially expressed FOXA1/A2 targets by Ingenuity
Pathway Analysis (Krämer et al., 2014) identified IL10RA as an inhibited upstream regulator
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(Table 4.3). Notably, IL10RA is a subunit of the receptor for the cytokine IL-10, and mice that are
IL-10-deficient develop chronic enterocolitis in response to bacterial colonization of the colon
(Berg et al., 1996; Kuhn et al., 1993). Thus, Foxa1/a2 ablation and disruption of IL-10 signaling
may result in the activation of similar proinflammatory pathways. Together, these data suggest
that targets of FOXA1/A2 in the colon regulate barrier function by maintaining the mucus layer
and modulating the mucosal inflammatory response to enteric pathogens.
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DISCUSSION
Aged Foxa1/a2 mutant colon shares several features with the Muc2

-/-

colon: a loss of

goblet cells, an increase in inflammatory cell infiltration, and altered crypt morphology. However,
as Muc2 is downregulated, but not completely absent from the Foxa1/a2-deficient colon, it is not
surprising that I did not observe the colorectal cancer phenotype that was seen in the aged Muc2null colon (Van der Sluis et al., 2006; Velcich, 2002).

The Kaestner lab had previously found

a decrease in the number of goblet cells and reduced Muc2 mRNA levels in 8-week-old
Foxa1/a2-deficient intestine, but did not detect an increase in inflammation or in the number of
+

-/-

BrdU cells (Ye and Kaestner, 2009). Conversely, as in Muc2 mice (Van der Sluis et al., 2006;
Velcich, 2002), proliferation was significantly increased in the colonic epithelium of our aged
Foxa1/a2 mutants.
There are two possible explanations for the discrepancy between young and aged
Foxa1/a2 mutants. First, the increase in inflammation and crypt proliferation seen in the aged
Foxa1/a2-deficient colon could be a secondary effect due to the decreased goblet cell number
and mucin secretion that begins early in life. The reduction in Muc2 mRNA levels, and therefore
decreased lubrication of the intestine, could cause microlesions, possibly resulting in impaired
barrier function and the increased inflammation observed in the aged mutant mice. Second, loss
of Foxa1/a2 could directly cause dysregulation of different pathways controlling mucosal health,
thus resulting in impaired barrier function, which can be compensated for in very young mice, but
becomes apparent only at an older age. Several findings, which I will discuss in detail below,
support the latter explanation.
Although microarray analysis of wild type and Muc2
colleagues revealed that Muc2

-/-

-/-

colonic epithelium by Yang and

colon displays a chronic subclinical inflammation phenotype, it

did not identify expression changes in glycosylation-related genes (Yang et al., 2008). This
suggests that the expression changes in our Foxa1/a2 mutants are not solely due to reduced
expression of Muc2. Moreover, expression of RELM-β is actually increased in Muc2

-/-

colon

(Yang et al., 2008), as opposed to the downregulation of RELM-β observed in Foxa1/a2-null
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colon (Figure 4.6C-E). Together, these data establish a distinctive role for the Foxa1/a2
transcription factors in the pathogenesis of colitis.
Remarkably, my findings also establish a regulatory role for the FOXA factors in the
transcription of the human IBD susceptibility locus Fut2 (Franke et al., 2010; Jostins et al., 2012;
McGovern et al., 2010). The FUT2-associated SNP rs516246 was identified by GWAS as an IBD
risk locus (Franke et al., 2010; Jostins et al., 2012). The same SNP was later established as an
IBD-associated expression quantitative trait locus (Singh, 2015). FUT2 is necessary for the
fucosylation of epithelial glycoproteins, which are the main components of the intestinal mucus
layer (Becker and Lowe, 2003; Wang et al., 2016). Optimal interactions between epithelial
glycoproteins and the luminal microbiome ensure colonization of the intestine with physiological
microflora, and therefore contribute to mucosal defense (Bergstrom and Xia, 2013; Hooper, 2004;
Patsos and Corfield, 2009). Interestingly, epithelial fucosylation of glycoproteins is induced in
mice treated with DSS (Terahara et al., 2011) as well as with toll-like receptor ligands (Pickard et
al., 2014), supporting the importance of fucosylation for maintaining or restoring the mucosal
barrier. My ChIP-seq data and the Fut2-downregulation in Foxa1/a2-mutants (Figure 4.5C and D)
demonstrate that FOXA factors control Fut2 and suggest that decreased fucosylation of intestinal
glycoconjugates contributes to impaired host-microbe crosstalk, concomitant with colonization of
the intestine by pathogenic flora and promotion of colitis.
In addition to FOXA1/A2 activating Fut2 expression, my data also suggest that
FOXA1/A2 co-regulates thousands of genes in concert with HNF4A. Given the requirement of
HNF4A for the development of the colonic epithelium and for the maturation of goblet cells
(Garrison et al., 2006), FOXA1/A2 likely cooperates with HNF4A in the regulation of genes
required for goblet cell differentiation and mucosal barrier maintenance. Furthermore, Hnf4α has
also been implicated by GWAS as an IBD risk locus (Barrett et al., 2009), and expression of
HNF4A is protective against inflammation (Chahar et al., 2014). Thus, inflammation in the
Foxa1/a2-null colonic epithelium may result from the loss of cooperative gene regulation by
FOXA1/A2 and HNF4A.
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In summary, deficiency of Foxa1/a2 in the gastrointestinal epithelium predisposes mice to
colitis, with the FOXA factors acting as central regulators of key genes influencing intestinal
epithelial barrier function (Figure 4.5). I provide a mechanistic explanation for the predisposition to
colitis seen in aged Foxa1/a2-mutant mice and link the observed phenotype to two genes, Fut2
and Hnf4α, for which single-nucleotide polymorphisms have been identified in GWAS for human
IBD. This highlights the role of FOXA1 and FOXA2 in intestinal epithelial health, and suggests
that

the

FOXA

factors

may

play

a

major
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role

in

human

IBD

pathogenesis.

FIGURES
Figure 4.1

Figure 4.1: Aged Foxa1/a2-null colon develops features of colitis. (A) Histological analysis of
aged control and Foxa1/a2 mutants shows spontaneous colitis in the absence of Foxa1/a2.
Hematoxylin and eosin (H&E) stained sections show increased crypt distortion, inflammatory cell
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infiltration, and goblet cell depletion. (B) CD45R staining for B-lymphocytes of the distal colon
(20x) reveals an increased number of lymphoid nodules in the Foxa1/a2 mutants. (C) CD3staining for T-lymphocytes of the distal colon (4x) shows occasional T-lymphocyte infiltration in
the control, but increased intraepithelial T-lymphocytes in the Foxa1/a2 mutants. (D) Blinded
histological damage scoring (maximum possible = 11) of H&E sections by a veterinary pathologist
reveals that colonic inflammation in aged mutants is significantly more severe than in age
matched controls. Each data point represents one mouse. (p = 0.0369).
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Figure 4.2

Figure 4.2: Foxa1/a2 mutant colonic epithelium exhibits significantly increased cell cycling as
well as altered differentiation. (A) Alcian blue staining of mucopolysaccharides in control and
Foxa1/a2 mutant colon of mice aged 14 months shows decreased mucin production in aged
Foxa1/a2 mutants (20x) (B) BrdU staining of control and Foxa1/a2 mutant colon of mice aged 14
months (20x). (C) Brdu-positive cells per crypt in proximal colon of mice aged 7-14 months.
Increased BrdU incorporation in aged Foxa1/a2 mutant epithelium indicates increased
proliferation. Each data point represents average BrdU-positive proximal colonic crypts per
mouse. (control n = 4, mutant n = 5; *p = 0.0317, Mann-Whitney test).
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Figure 4.3

Figure 4.3: The antibodies directed against FOXA1 (ab23738) and FOXA2 (sc-6554), which were
used to perform ChIP-seq, do not cross-react. The antibodies were validated by using each of
them to perform ChIP in (A) Foxa1-null liver lysates and (B) Foxa2-null liver lysates followed by
qPCR for the FOXA liver target Cdx2. Binding of the Cdx2 promoter by the FOXA antibodies was
depleted in liver lysates lacking their respective target proteins.
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Figure 4.4

Figure 4.4: FOXA1 and FOXA2 bind overlapping targets in the colonic epithelium. (A) Scatterplot of average normalized peak height in reads per million (RPM) of 4,702 regions from the union
of FOXA1 and FOXA2 ChIP-seq peaks. Diagonal blue line marks y = x. Gray error bars indicate
SEM. (B) De novo motif analysis of regions bound by both FOXA1 and FOXA2 identified the
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Foxa consensus site as being the most enriched (p = 2.2x10

-638

). The de novo motif had high
-9

identity to both the FOXA1 and the FOXA2 canonical motifs (FOXA1, p = 2.32x10 ; FOXA2, p =
-16

1.71x10 ). (C) Frequency of FOXA1/A2-bound regions binned by distance to TSS. (D)
Enrichment of FOXA1/A2 binding at genomic regions compared to the frequency of the region in
the genome. (E) De novo motif analysis of Foxa1/A2-bound regions identified an HNF4A-like
-6

motif as being significantly enriched (p = 2.45x10 ). (F) There is significant overlap between the
genes identified as being FOXA targets and the genes identified as being HNF4A targets in the
colon, which may indicate co-regulation by the two proteins. (p= 2.34x10
test).
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-279

, hypergeometric

Table 4.1: Differentially expressed FOXA1/A2 target genes (FDR<0.05) in mutant colonic
epithelium
Gene Symbol
UCSC Transcript ID
Log2(Mut. RPM/Cntrl. RPM)
FDR
Defa6
uc009lbx.2
-6.88
1.37E-02
Sycn
uc009fzf.2
-6.30
1.30E-32
Insrr
uc008psy.2
-4.89
1.62E-10
Rgs17
uc007egh.2
-4.61
4.50E-07
Pitx2
uc008rhx.1
-4.42
1.15E-02
Fut9
uc008sei.1
-4.07
1.47E-05
Sult1c2
uc008czu.1
-4.01
6.40E-10
Aqp4
uc008edr.2
-3.97
8.04E-06
Cubn
uc008ijz.1
-3.76
8.92E-09
Reg4
uc008qpq.1
-3.50
6.60E-05
A4gnt
uc009rej.2
-3.47
3.53E-07
Foxa1
uc007nps.1
-3.46
4.95E-21
Itih2
uc008ihq.2
-3.44
3.82E-02
Nov
uc007vrn.1
-3.23
1.82E-02
Retnlb (Relm-β)
uc007zju.1
-3.18
9.53E-05
Capn8
uc011wxv.1
-3.08
1.75E-03
Car2
uc008oqt.2
-3.05
2.99E-10
Chga
uc007oui.1
-2.87
1.56E-12
Ephx4
uc008yme.1
-2.83
1.72E-03
2810459M11Rik
uc011wog.1
-2.80
1.30E-12
Samd5
uc007eiw.1
-2.75
9.85E-03
Gna14
uc008gwu.2
-2.61
6.31E-03
Pkhd1
uc007akv.1
-2.61
9.23E-04
Car8
uc008rxv.1
-2.59
2.09E-10
Mmp15
uc009myh.1
-2.55
4.45E-09
Adamts15
uc009oqz.1
-2.51
1.13E-03
Cyp4b1
uc008ufc.1
-2.49
2.09E-10
Slc45a3
uc007cnz.1
-2.45
4.19E-07
B3gnt6
uc009ikf.1
-2.41
1.46E-03
Pla2g10
uc007ygi.1
-2.22
1.64E-05
Pllp
uc009mwv.1
-2.20
1.28E-06
Aldh1l1
uc009cxm.1
-2.10
1.55E-03
Paqr8
uc007ald.1
-2.10
2.87E-02
Kcne3
uc009imp.2
-2.06
2.11E-07
Ak4
uc008tvo.2
-2.01
2.22E-02
Gstm3
uc008qxv.1
-2.00
2.19E-02
Maob
uc009ssb.2
-1.94
8.18E-04
Ccl6
uc007kpm.1
-1.93
2.30E-05
2210407C18Rik
uc007jbw.2
-1.76
5.25E-03
Arhgap20
uc009plj.1
-1.74
3.02E-04
Ptprn2
uc007phx.2
-1.72
6.99E-03
Mkx
uc008dzp.2
-1.72
3.19E-03
Mpst
uc007wpf.2
-1.69
2.59E-02
Atp2c2
uc009nqg.1
-1.64
2.17E-02
Ramp1
uc007bzx.2
-1.58
5.43E-03
Igdcc4
uc012gvg.1
-1.57
2.29E-03
Gcnt3
uc009qnt.1
-1.55
8.26E-04
Cd177
uc009fql.1
-1.55
1.69E-02
Bace2
uc008ade.2
-1.54
1.58E-03
Muc2
uc009kma.2
-1.53
1.72E-02
Rnase4
uc007tmo.2
-1.51
2.19E-03
Nupr1
uc009jsd.1
-1.51
8.69E-03
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Hsd17b2
Gmds
Pde8b
Fut2
Ffar2
Smpd3
Wfdc2
Fam83e
Sgsm3
Tlr1
Slco2a1
Cyp2s1
Acsm3
Sord
Far1
Pim3
Cytip
Pou2af1
Pdk4
Gcnt1
Rdh12
Maf
Ccl25
Ereg
Trim29
Pla2g2f
Slc34a2
Cck
Nav3
Fabp7
Pcdh17
Pnoc
Kdm5d
Eif2s3y

uc009npf.1
uc007pzq.1
uc007rmd.2
uc009gwn.1
uc009ggn.1
uc009nfx.1
uc008nve.1
uc009gwy.1
uc007wwb.2
uc008xmw.1
uc009rgd.1
uc009fua.1
uc009jlq.1
uc008maj.1
uc009jhp.1
uc007xeq.1
uc008jsi.1
uc009plg.1
uc009awk.1
uc008gxn.2
uc011yog.1
uc009nof.1
uc009ktw.2
uc008ybs.1
uc009pbi.2
uc008vlf.2
uc008xlb.2
uc009sdg.2
uc007gzl.1
uc007fct.1
uc007utp.2
uc007uji.1
uc009uzb.1
uc009uzd.1

-1.47
-1.38
-1.35
-1.35
-1.34
-1.26
-1.24
-1.22
-1.22
-1.22
-1.22
-1.20
-1.18
-1.13
-1.11
-1.04
1.28
1.78
1.86
1.93
2.26
2.38
2.45
2.70
2.73
3.09
3.10
3.22
3.56
3.77
3.94
6.19
7.68
9.18
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3.58E-03
7.76E-03
3.33E-03
1.75E-03
1.94E-02
7.05E-03
1.97E-02
1.12E-02
3.41E-02
7.05E-03
2.66E-02
5.12E-03
3.82E-02
3.61E-02
2.82E-02
4.21E-02
1.47E-02
1.45E-02
1.78E-07
4.01E-05
3.82E-02
4.11E-06
5.02E-03
4.59E-07
1.07E-02
8.31E-03
6.40E-10
1.45E-06
1.01E-03
2.03E-03
1.75E-03
2.29E-06
3.31E-05
3.37E-06

Table 4.2 Top 25 disease and functional annotations associated with differentially
expressed, FOXA1/A2-bound genes
Categories
Diseases or
P-Value
Molecules
Functions
Annotation
Cancer, Organismal Injury
uterine serous
8.93E-05
CAR2, MAF, PDE8B,
and Abnormalities,
papillary cancer
PLLP, RAMP1, RNASE4,
Reproductive System
WFDC2
Disease
Molecular Transport
transport of carbon
1.51E-04
AQP4, CAR2
dioxide
Lipid Metabolism, Small
synthesis of fatty
1.51E-04
ACSM3, EREG, FAR1,
Molecule Biochemistry
acid
FOXA1, PDK4,
PLA2G10, PNOC,
SLC45A3
Tissue Morphology
abnormal
1.75E-04 A4GNT, CCL25, GCNT1,
morphology of
GCNT3, MMP15, MUC2
membrane tissue
Post-Translational
glycosylation of
1.93E-04
A4GNT, FUT2, FUT9,
Modification
protein
GCNT1, GCNT3
Digestive System
function of intestine 2.20E-04
KCNE3, MUC2,
Development and Function,
SLC34A2
Organ Development
Developmental Disorder,
hyperkalemic
2.26E-04
CAR2, KCNE3
Hematological Disease,
periodic paralysis
Hereditary Disorder,
Metabolic Disease,
Neurological Disease,
Organismal Injury and
Abnormalities, Skeletal and
Muscular Disorders
Cancer, Organismal Injury
female genital tract 2.36E-04
CA2, MAF, NAV3,
and Abnormalities,
serous carcinoma
PDE8B, PDK4, PLLP,
Reproductive System
RAMP1, RNASE4,
Disease
WFDC2
Lipid Metabolism, Small
fatty acid
2.70E-04
ACSM3, EREG, FABP7,
Molecule Biochemistry
metabolism
FAR1, FOXA1, PDK4,
PLA2G10, PNOC,
SLC45A3, SLCO2A1,
SMPD3
Auditory Disease,
contact dermatitis of 3.16E-04
CYTIP, PLA2G2F
Dermatological Diseases
ear
and Conditions,
Immunological Disease,
Inflammatory Disease,
Inflammatory Response,
Organismal Injury and
Abnormalities
Digestive System
abnormal
3.20E-04
GCNT1, GCNT3, MUC2
Development and Function,
morphology of
Gastrointestinal Disease,
intestinal mucosa
Organ Morphology,
Organismal Development,
Organismal Injury and
Abnormalities, Tissue
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Morphology
Cancer, Gastrointestinal
Disease, Organismal Injury
and Abnormalities
Post-Translational
Modification
Organismal Injury and
Abnormalities
Organismal Development

hyperplasia of
stomach tissue

6.72E-04

A4GNT, KCNE3

O-glycosylation of
protein
lithiasis

7.86E-04

A4GNT, GCNT1, GCNT3

8.41E-04

development of
genitourinary
system

9.70E-04

Inflammatory Response

inflammatory
response

9.88E-04

Post-Translational
Modification
Ophthalmic Disease,
Organismal Injury and
Abnormalities
Lipid Metabolism, Small
Molecule Biochemistry

O-mannosylation of
protein
cataract disease

1.35E-03

CAR2, CUBN, GNA14,
SLC34A2
Eif2s3y, EREG, FABP7,
GCNT1, GCNT3,
HSD17B2, KDM5D,
MMP15, MPST, NUPR1,
PKHD1, PTPRN2,
SMPD3, WFDC2
CCL25, CHGA, GCNT1,
KCNE3, MAF, MAOB,
NOV, NUPR1, PLA2G10,
PNOC, RETNLB, TLR1
GCNT1, GCNT3

1.37E-03

MAF, NOV, PITX2,
SORD

synthesis of lipid

1.42E-03

Amino Acid Metabolism

quantity of amino
acids
metabolism of
carbohydrate

1.56E-03

quantity of
monoamines

1.87E-03

ACSM3, EREG, FAR1,
FOXA1, HSD17B2,
PDE8B, PDK4,
PLA2G10, PNOC,
SLC45A3, SMPD3
AQP4, CUBN, FUT2,
PDK4, SMPD3
A4GNT, CCK, CHGA,
FUT2, FUT9, GCNT3,
GMDS, PLA2G10,
RETNLB, SORD
AQP4, CHGA, MAOB,
MPST, PTPRN2

anxiety-like behavior
serous
adenocarcinoma

1.96E-03
1.96E-03

morphology of body
cavity

2.16E-03

Carbohydrate Metabolism

Cell-To-Cell Signaling and
Interaction, Molecular
Transport, Small Molecule
Biochemistry
Behavior
Cancer, Organismal Injury
and Abnormalities
Organismal Development
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1.62E-03

CCK, PNOC, PTPRN2
CAR2, MAF, NAV3,
PDE8B, PDK4, PLLP,
RAMP1, RDH12,
RNASE4, WFDC2
A4GNT, CCK, CCL25,
CHGA, GCNT1, GCNT3,
HSD17B2, KCNE3,
MMP15, MUC2, NOV,
NUPR1, PITX2, PKHD1,
RETNLB, SLCO2A1,
SMPD3

Figure 4.5

Figure 4.5: Genes involved in mucosal barrier function are bound by FOXA1/A2 and HNF4A.
Genome browser images displaying FOXA1/A2 and HNF4A binding (blue), transcription in control
colonic epithelium (green), and Foxa1/a2-null colonic epithelium (red) at the genomic loci of (A)
Muc2, (C) Fut2, (E) B3gnt6, and (G) Gcnt3. (B, D, F, and H) Validation of RNA-seq transcript
levels by RT-qPCR (*p < 0.05; Student’s t-test).
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Figure 4.6

Figure 4.5: Genes involved in mucosal inflammatory response are bound by FOXA1/A2 and
downregulated in Foxa1/a2-null colonic epithelium. (A) Genome browser images displaying
FOXA1/A2 and HNF4A binding (blue), transcription in control colonic epithelium (green), and
Foxa1/a2-null colonic epithelium (red) at theTlr1 locus. (B) Validation of Tlr1 RNA-seq transcript
levels by RT-qPCR. (C) Genome browser images displaying FOXA1/A2 binding (blue),
transcription in control colonic epithelium (green), and Foxa1/a2-null colonic epithelium (red) at
the Relm-b locus. Relm-b is not bound by HNF4A. (D) Validation of Relm-b RNA-seq transcript
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levels by RT-qPCR. (E) RELM-b staining in control and Foxa1/a2 mutant colon of mice aged 14
months shows significant RELM-b depletion in mutant goblet cells (10x).
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Table 4.3: Predicted upstream regulators of differentially expressed, FOXA1/A2-bound
genes
Upstream Regulator
IL10RA
HNF1A
miR-6742-3p (miRNAs w/seed
CCUGGGU)
tretinoin
miR-204-5p (and other miRNAs
w/seed UCCCUUU)
calcitriol
miR-204-3p (and other miRNAs
w/seed CUGGGAA)
miR-92a-1-5p (miRNAs w/seed
GGUUGGG)
miR-3083-5p (and other miRNAs
w/seed GGCUGGG)

Molecule Type

Predicted
Activation State
Inhibited

5.49E-08

Inhibited

4.53E-04

mature microrna

Activated

5.15E-04

chemical - endogenous
mammalian
mature microrna

Inhibited

2.62E-03

Activated

6.29E-03

chemical drug

Inhibited

6.87E-03

mature microrna

Activated

1.15E-02

mature microrna

Activated

2.88E-02

mature microrna

Activated

3.44E-02

transmembrane
receptor
transcription regulator
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P-value

CHAPTER 5
Conclusions and Future Directions
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The incidence of IBD in Westernized countries has increased significantly during the last
century. Factors contributing to this increase include improved diagnosis due to improved medical
technology and access to healthcare, and a spread of the Westernized lifestyle. Notably, IBD
incidence has increased Asia, the Middle East, and South America alongside the industrialization
of those regions (Kaplan and Ng, 2016). Thus, IBD is a condition with ever-increasing worldwide
significance. As IBD is a chronic condition with an increasing prevalence, the global burden of
caring for an aging population of IBD patients is expected to increase even further in the coming
decade (Kaplan and Ng, 2016). Early treatment of IBD is key to preventing disease progression
and the development of complications (Colombel et al., 2016). Therefore, it is important to
understand the pathogenesis of IBD in order to improve treatment outcomes and to prevent the
devastating sequelae such as colorectal cancer.

The molecular pathogenesis of colitis in the Foxa1/a2-mutant mouse
The study of mouse models of colitis has led to a better understanding of the molecular
pathogenesis of IBD and the role that the immune response has in etiology of the disease.
Characterization of mice deficient for interleukin 10 (IL-10), a suppressor of macrophage
activation(Ren et al., 1991), uncovered altered MUC2 expression in colitis. In response to
exposure to bacteria, IL-10-deficient mice develop colitis and display reduced in MUC2 synthesis
in comparison to controls, as well as reduced post-translational MUC2 sulfation (Schwerbrock et
al., 2004). This discovery stimulated detailed analyses of mice homozygous for a Muc2-null allele
in order to gain insight into the role of MUC2 in colonic barrier protection, as well as its possible
role in IBD. The importance of MUC2 as a component of the barrier is illustrated by the fact that
Muc2-mutant mice develop spontaneous intestinal inflammation that becomes exacerbated with
age, and eventually leads to colorectal cancer (Van der Sluis et al., 2006; Velcich, 2002).
Analysis of upstream regulators of Muc2 revealed that the Muc2 promoter is bound in vivo by the
transcription factors FOXA1 and FOXA2 and that they are capable of activating the Muc2
promoter in vitro (van der Sluis et al., 2008; Ye and Kaestner, 2009).
In my thesis work, through cistromic and transcriptomic analyses, I have established that
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in the mature colon, FOXA1 and FOXA2 direct transcription not only of Muc2, but of a network of
genes required for the normal differentiation of secretory cells, the maintenance of the mucus
layer, and for defense against microbial challenge. Like in the colon, FOXA1/A2 is required for the
differentiation and function of other secretory organs, including the liver (Bochkis et al., 2012; Lee
et al., 2005), pancreas (Gao et al., 2008; Kaestner et al., 1999), and lungs (Wan et al., 2004,
2005). However, I have also shown that, although FOXA is required in each of these
developmentally related organs, FOXA1 and FOXA2 have distinct colon-specific functions. For
example, while FOXA2 regulates expression of mucins in both the lungs and the colon, in the
lungs FOXA2 directly inhibits transcription of the gel-forming mucin Mucin5ac (Muc5ac) (Wan et
al., 2004), but in the colon FOXA2 activates expression of Muc2.
Furthermore, I have shown that genomic binding enrichment of FOXA1 and FOXA2
differs between the colon and other organs. In contrast to the colon, ChIP-seq experiments on
adult murine liver revealed that FOXA1 and FOXA2 occupy an overlapping set of targets, but
thousands of genes are uniquely bound by either FOXA1 or FOXA2. Additionally, most
FOXA1/FOXA2 co-occupied regions in the liver are at distal enhancers (Bochkis et al., 2012).
Conversely, my ChIP-seq data demonstrate that in the colon, FOXA1 and FOXA2 share nearly
identical sets of binding sites. Moreover, as opposed to in the mature liver, I have shown that
FOXA binding is enriched at transcriptional start sites in the colon, which suggests that the
FOXAs co-regulate transcription by binding both enhancers and promoters.
My data show that, in addition to Muc2, direct targets of FOXA1/A2 in the colon include
the O-glycosyltransferase genes B3gnt6 and Gcnt3, and the fucosyltransferase gene Fut2. The
Kaestner lab had previously reported that the number of goblet cells is decreased and Muc2
mRNA levels are reduced in the 8-week-old Foxa1/a2-deficient intestine (Ye and Kaestner,
2009). Likewise, I have shown in vivo that ablation of Foxa1/a2 results in a significant decrease of
colon Muc2 steady state transcription levels in aged mutants.
Although the requirement of FOXA1/A2 for expression of MUC2 had already been
established, I have expanded our understanding of the role of FOXA in the formation of the
colonic mucus layer by identifying regulatory targets that are required for the post-translational
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modification of mucins. Importantly, I have shown that transcript levels for B3gnt6, which is
required to produce core 3-derived O-glycans, and for Gcnt3, which produces core 2- and core 4derived O-glycans, are also significantly decreased in Foxa1/a2-null colon compared to agematched controls. Notably, core 3-derived O-glycans are restricted primarily to the salivary glands
and the intestinal tract (Bergstrom and Xia, 2013; Honke and Taniguchi, 2002; Iwai et al., 2002)
and MUC2 O-glycan modifications are mostly derived from core 1 and core 3 structures
(Bergstrom and Xia, 2013). Thus, adequate levels of B3GNT6 are imperative for the posttranslational processing of MUC2.
Thus far, although the evidence is persuasive, I have not directly shown that binding by
FOXA1/A2 at the promoters of my proposed target genes is required for their transcription.
Furthermore, I have yet to show that these binding sites are required for target gene expression
in humans. Given the potential for off-target effects in a physiologically artificial system like a
luciferase reporter assay, which includes the possibility of increased aberrant promoter binding by
FOXA to weak targets as a result of overexpression, I have instead opted to utilize the
CRISPR/Cas9 system to specifically delete the FOXA binding motif at potential target genes in
human colon cell lines. Given that many enhancers contain evolutionarily conserved sequences
(Heintzman et al., 2009), and also that FOXA2 binding data are available in the Caco-2 colorectal
adenocarcinoma cell line (Gosalia et al., 2015), I was able to identify FOXA2-bound enhancers in
human cells that correspond to the FOXA1/A2 target regions I had mapped in mouse colonic
crypts. Through the CRISPR/Cas9-mediated insertion of indels into these regions, I expect that I
will be able to disrupt FOXA1/A2 binding, which will then result in the downregulation of target
genes if indeed the FOXA proteins regulate these genes by direct binding to their promoters.

Altered glycoprotein composition in FOXA1/A2-deficient colon
The extensive O-glycan modifications on MUC2 give it a high capacity to bind water,
which contributes substantially to its ability to form the viscoelastic gel bilayer in the colon. While
the glycan modifications in the outer, less viscous layer of mucus serve as both an attachment
site and an energy source for bacteria (Johansson et al., 2011), the viscous inner layer is
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impenetrable to bacteria, and thus is maintained as a sterile environment between lumenal
antigens and the epithelial surface (Johansson et al., 2008). Not surprisingly, mice homozygous
for the B3gnt6-null allele, and consequently unable to produce core 3-derived O-glycans, also
produce significantly less MUC2 protein. As I observed in FOXA1/A2-deficient colon, B3gnt6mutants present with an inflammatory phenotype that includes increased inflammatory cell
infiltration and an increased epithelial proliferation rate (An et al., 2007).
Compounding the potential deleterious effects of Muc2 and B3gnt6 downregulation in the
aged Foxa1/a2 mutant colon, I have also shown that steady state transcript levels are
significantly decreased for the FOXA binding target Fut2. FUT2 catalyzes the transfer of GDPfucose, the final step of H blood group antigen synthesis, in salivary and other epithelial
secretions (Kelly et al., 1995). Although the H cell surface antigen is associated with blood type, it
also plays a role in host-microbe interactions in the gut (Becker and Lowe, 2003). As fucose is
used as an energy source by commensal bacteria, the host may regulate fucose production in
order to influence the composition of the gut microbiome (Hooper, 2004). In support of this idea,
epithelial fucosylation of glycoproteins is induced in mice treated with toll-like receptor ligands
(Pickard et al., 2014). Furthermore, mice that have a GDP-fucose deficiency have increased
epithelial

permeability

and

spontaneously

develop

colitis,

dysplasia,

and,

ultimately,

adenocarcinoma (Wang et al., 2016).
Importantly, in humans the FUT2-associated SNP rs516246, which was first identified by
GWAS as an IBD risk locus (Franke et al., 2010; Jostins et al., 2012; McGovern et al., 2010), has
also been established as an IBD-associated expression quantitative trait locus (Singh et al.,
2015). Additionally, abnormal glycosylation has been observed in patients with inflammatory
bowel disease (Podolsky and Fournier, 1988), in addition to being present in the colonic mucosa
of patients during malignant transformation (Boland et al., 1982). Thus, my data suggest that
host-microbe crosstalk may be perturbed in the Foxa1/a2-mutant colon as a result of inhibited
glycosylation, resulting in colonization of the intestine by pathogenic microflora, thus modeling
certain aspects of inflammatory bowel disease.
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Although my data provide compelling evidence for disrupted MUC2 glycoconjugation that
leads to dysbiosis, I have yet to directly show that mucus composition is altered in Foxa1/a2mutant colon, or that bacterial interactions with the mucosa are altered in mutants. In healthy
colon tissue, the Tn antigen that serves as the foundation for O-type glycosylation is normally
masked by additional glycans and is thus virtually undetectable by antibody staining. However, in
colon cancer, glycosylation is frequently disrupted and unmodified Tn antigen can be detected
(Itzkowitz et al., 1991). Therefore, in the future, I plan to demonstrate the reduction of O-glycan
biosynthesis by staining for Tn antigen in mutant and control epithelium.
Despite the significantly increased histological damage scores and the considerably
+

increased number of CD45R lymphoid nodules in aged Foxa1/a2 mutants compared to agematched controls, I have not yet directly shown that there is an increase in the permeability of the
colonic mucus layer in mutants. Thus, in order to confirm compromised barrier function in
Foxa1/a2-mutant colon, I plan to visualize bacterial localization relative to the mucus layer by
fluorescence in situ hybridization in tandem with MUC2 staining, as described by Johansson and
Hansson (Hill and Button, 2012). MUC2 that lacks glycan branches would not only have an
impaired ability to bind water (Johansson et al., 2011), but would also leave the protein core
exposed to proteolytic cleavage by bacteria (Van Der Post et al., 2013). Therefore, I expect that
the normally thick, sterile mucus layer would be thinner and allow the epithelium to be directly
apposed to resident microbiota in Foxa1/a2 mutant colon.

Application of the colonic FOXA1/A2 cistrome to IBD risk locus prediction
In addition to the environmental triggers of disease, GWAS has identified over 200 IBD
risk loci, which have implicated genes involved pathways including innate and adaptive immunity,
ER stress, autophagy, microbial defense, and intestinal barrier function (Jostins et al., 2012;
Kaplan and Ng, 2016). However, numerous IBD risk loci have also been identified in intergenic
regions, emphasizing the need to identify enhancer elements in order to understand the effects of
disease-associated mutations at these loci on gene regulatory networks.
Many enhancers contain evolutionarily conserved sequences and are frequently marked
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by H3K4me1 enrichment, as well as acetylation of H3K27 (Heintzman et al., 2009). Given the
requirement of FOXA for the maintenance of chromatin accessibility at enhancer regions in the
liver (Iwafuchi-Doi et al., 2016), I expect that by aligning human colonic FOXA ChIP-seq data with
maps of H3K4me1 and H3K27ac enrichment in the colonic epithelium, I will be able to identify
evolutionarily conserved colon-specific enhancers. At present, there are no FOXA occupancy
data available for human colonic epithelium. Therefore, I plan to perform ChIP-seq in colonic
human crypts for both FOXA1 and FOXA2.

Foxa1/a2 in Barrett’s esophagus
In addition to better understanding IBD etiology, studying the developmental pathways
regulated by FOXA1/A2 may also aid in the investigation of Barrett’s esophagus (BE)
pathogenesis. BE is characterized by the presence of intestinal columnar epithelial cells,
enteroendocrine cells, Paneth cells, and MUC2-expressing goblet cells in the esophagus.
Intestinal metaplasia in the esophagus is thought to develop as a result of chronic
gastroesophageal reflux, which may activate intestinal transcription factors, such as CDX2 and
FOXA2. The risk of developing esophageal adenocarcinoma (EAC) is substantially increased in
patients with BE compared to the general population, however EAC pathogenesis is still not well
understood (Chen et al., 2011).
FOXA2 is highly expressed in the columnar embryonic esophageal epithelium, but not in
the mature squamous esophageal epithelium. However, FOXA2 is expressed in human BE,
dysplasia, and EAC. Additionally, though FOXA1 is expressed in the squamous epithelium of the
esophagus (Besnard et al., 2004), it is overexpressed in EAC (Lin et al., 2002). Notably,
overexpression of FOXA2 in human esophageal squamous epithelial cells induces expression of
MUC2 and AGR2, which is a protein found in the ER of intestinal secretory cells and is required
for folding MUC2 (Wang et al., 2014).
It has been shown that environmental stimuli, such as tissue damage from acid reflux,
may activate developmental signaling pathways resulting in one type of tissue abnormally giving
rise to cells of a different, but embryonically related, tissue (Tosh and Slack, 2002). In the liver,
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the enhancer of Cdx2, which is transcriptionally silent, is co-occupied by FOXA2 and the
repressive transcription factor RFX1. Likewise, in the normal esophageal epithelium, there is high
expression of RFX1, but CDX2 is undetectable. Notably, in vitro, Cdx2 transcription is enhanced
by the deletion of its associated RFX1 binding motif, suggesting that RFX1 suppresses activity of
FOXA2-occupied enhancers. In addition, in the intestinal metaplastic epithelium of humans with
the Barrett’s esophagus with dysplasia and EAC, RFX1 expression is significantly downregulated
(Watts et al., 2011). Thus, FOXA may initiate the intestinal differentiation program in nonintestinal epithelium by activating transcription of the network of genes that are required for the
differentiation of colonic secretory cells.

93

CHAPTER 6

BIBLIOGRAPHY

94

Abraham, C., and Cho, J.H. (2009). Inflammatory Bowel Disease. N. Engl. J. Med. 2066–2078.
Alder, O., Cullum, R., Lee, S., Kan, A.C., Wei, W., Yi, Y., Garside, V.C., Bilenky, M., Griffith, M.,
Morrissy, A.S., et al. (2014). Hippo signaling influences HNF4A and FOXA2 enhancer
switching during hepatocyte differentiation. Cell Rep. 9, 261–271.
Altmann, G.G. (1972). Influence of starvation and refeeding on mucosal size and epithelial
renewal in the rat small intestine. Am. J. Anat. 133, 391–400.
An, G., Wei, B., Xia, B., McDaniel, J.M., Ju, T., Cummings, R.D., Braun, J., and Xia, L. (2007).
Increased susceptibility to colitis and colorectal tumors in mice lacking core 3–derived Oglycans. J. Exp. Med. 204, 1417–1429.
Ananthakrishnan, A.N. (2015). Epidemiology and risk factors for IBD. Nat. Rev. Gastroenterol.
Hepatol. 12, 205–217.
Ang, S., and Rossant, J. (1994). HNF3b is essential for Node and Notocohord Formation in
mouse development. Cell 78, 561–574.
Aoki, R., Shoshkes-Carmel, M., Gao, N., Shin, S., May, C.L., Golson, M.L., Zahm, A.M., Ray, M.,
Wiser, C.L., Wright, C.V.E., et al. (2016). Foxl1-Expressing Mesenchymal Cells Constitute
the Intestinal Stem Cell Niche. Cell. Mol. Gastroenterol. Hepatol. 2, 175–188.
Azzaria, M., Goszczynski, B., Chung, M. a, Kalb, J.M., and McGhee, J.D. (1996). A fork
head/HNF-3 homolog expressed in the pharynx and intestine of the Caenorhabditis elegans
embryo. Dev. Biol. 178, 289–303.
Barrett, J.C., Lee, J.C., Lees, C.W., Prescott, N.J., Anderson, C.A., Phillips, A., Wesley, E.,
Parnell, K., Zhang, H., Drummond, H., et al. (2009). Genome-wide association study of
ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. Nat.
Genet. 41, 1330–1334.
Baumgart, D.C., and Sandborn, W.J. (2012). Crohn’s disease. Lancet 380, 1590–1605.
Becker, D.J., and Lowe, J.B. (2003). Fucose: Biosynthesis and biological function in mammals.
Glycobiology 13.
Berg, D.J., Davidson, N., Kuhn, R., Muller, W., Menon, S., Holland, G., Thompson-Snipes, L.,
Leach, M.W., and Rennick, D. (1996). Enterocolitis and colon cancer in interleukin-10deficient mice are associated with aberrant cytokine production and CD4+ Th1-like
responses. J. Clin. Invest. 98, 1010–1020.
Bergstrom, K.S.B., and Xia, L. (2013). Mucin-type O-glycans and their roles in intestinal
homeostasis. Glycobiology 23, 1026–1037.
Besnard, V., Wert, S.E., Hull, W.M., and Whitsett, J.A. (2004). Immunohistochemical localization
of Foxa1 and Foxa2 in mouse embryos and adult tissues. Gene Expr. Patterns 5, 193–208.
Bochkis, I.M., Schug, J., Ye, D.Z., Kurinna, S., Stratton, S.A., Barton, M.C., and Kaestner, K.H.
(2012). Genome-wide location analysis reveals distinct transcriptional circuitry by paralogous
regulators Foxa1 and Foxa2. PLoS Genet. 8.
Boland, C.R., Montgomery, C.K., and Kim, Y.S. (1982). Alterations in human colonic mucin
occurring with cellular differentiation and malignant transformation. Proc. Natl. Acad. Sci. 79,
2051–2055.

95

Boza, J.J., Möennoz, D., Vuichoud, J., Jarret, a R., Gaudard-de-Weck, D., Fritsché, R., Donnet,
a, Schiffrin, E.J., Perruisseau, G., and Ballévre, O. (1999). Food deprivation and refeeding
influence growth, nutrient retention and functional recovery of rats. J. Nutr. 129, 1340–1346.
Chahar, S., Gandhi, V., Yu, S., Desai, K., Cowper-Sal Lari, R., Kim, Y., Perekatt, A.O., Kumar, N.,
Thackray, J.K., Musolf, A., et al. (2014). Chromatin Profiling Reveals Regulatory Network
Shifts and a Protective Role for HNF4A during Colitis. Mol. Cell. Biol.
Chen, H., Fang, Y., Tevebaugh, W., Orlando, R.C., Shaheen, N.J., and Chen, X. (2011).
Molecular mechanisms of Barrett’s esophagus. Dig. Dis. Sci. 56, 3405–3420.
Chen, W., Böcker, W., Brosius, J., and Tiedge, H. (1997). Expression of neural BC200 RNA in
human tumours. J. Pathol. 183, 345–351.
Cheng, H., and Leblond, C.P. (1974). Origin, differentiation and renewal of the four main epithelial
cell types in the mouse small intestine V. Unitarian theory of the origin of the four epithelial
cell types. Am. J. Anat. 141, 537–561.
Chesnokov, I., Chu, W.M., Botchan, M.R., and Schmid, C.W. (1996). p53 inhibits RNA
polymerase III-directed transcription in a promoter-dependent manner. Mol. Cell. Biol. 16,
7084–7088.
Chin, A.M., Tsai, Y.H., Finkbeiner, S.R., Nagy, M.S., Walker, E.M., Ethen, N.J., Williams, B.O.,
Battle, M.A., and Spence, J.R. (2016). A Dynamic WNT/Beta-CATENIN Signaling
Environment Leads to WNT-Independent and WNT-Dependent Proliferation of Embryonic
Intestinal Progenitor Cells. Stem Cell Reports 7, 826–839.
Cirillo, L.A., Lin, F.R., Cuesta, I., Friedman, D., Jarnik, M., and Zaret, K.S. (2002). Opening of
compacted chromatin by early developmental transcription factors HNF3 (FoxA) and GATA4. Mol. Cell 9, 279–289.
Clark, K.L., Halay, E.D., Lai, E., and Burley, S.K. (1993). Co-crystal structure of the HNF-3/fork
head DNA-recognition motif resembles histone H5. Nature 364, 412–420.
Clevers, H., Loh, K.M., and Nusse, R. (2014). Stem cell signaling. An integral program for tissue
renewal and regeneration: Wnt signaling and stem cell control. Science 346, 1248012.
Colombel, J.-F., Narula, N., and Peyrin-Biroulet, L. (2016). Management Strategies to Improve
Outcomes of Patients with Inflammatory Bowel Diseases. Gastroenterology 152, 351–361.e5.
Corfield, A.P., Carroll, D., Myerscough, N., and Probert, C.S.J. (2001). [Frontiers in Bioscience 6,
d1321-1357, October 1, 2001] MUCINS IN THE GASTROINTESTINAL TRACT IN HEALTH
AND DISEASE Anthony P. Corfield, Daniel Carroll, Neil Myerscough and Christopher S.J.
Probert. 1321–1357.
Dahlhamer, J.M., Zammitti, E.P., Ward, B.W., Wheaton, A.G., and Croft, J.B. (2016). Prevalence
of Inflammatory Bowel Disease Among Adults Aged ≥ 18 Years — United States , 2015. 65,
1166–1169.
Danese, S., and Fiocchi, C. (2011). Ulcerative colitis. N. Engl. J. Med. 365, 1713–1725.
Dianda, L., Hanby, A., Wright, N., Sebesteny, A., Hayday, A., and Owen, M.J. (1997). T cell
receptor-alpha beta-deficient mice fail to develop colitis in the absence of a microbial
environment. Am. J. Pathol. 150, 91–97.
Duchmann, R., May, E., Heike, M., Knolle, P., Neurath, M., Meyer zum Buschenfelde, K.H., and
zum Buschenfelde, K.-H.M. (1999). T cell specificity and cross reactivity towards
enterobacteria, Bacteroides, Bifidobacterium, and antigens from resident intestinal flora in

96

humans. Gut 44, 812–818.
Dufort, D., Schwartz, L., Harpal, K., and Rossant, J. (1998). The transcription factor HNF3beta is
required in visceral endoderm for normal primitive streak morphogenesis. Development 125,
3015–3025.
Dumay-Odelot, H., Durrieu-Gaillard, S., Da Silva, D., Roeder, R.G., and Teichmann, M. (2010).
Cell growth- and differentiation-dependent regulation of RNA polymerase III transcription. Cell
Cycle 9, 3687–3699.
van Es, J.H., van Gijn, M.E., Riccio, O., van den Born, M., Vooijs, M., Begthel, H., Cozijnsen, M.,
Robine, S., Winton, D.J., Radtke, F., et al. (2005). Notch/gamma-secretase inhibition turns
proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 435, 959–963.
Farhat, K., Riekenberg, S., Heine, H., Debarry, J., Lang, R., Mages, J., Buwitt-Beckmann, U.,
Röschmann, K., Jung, G., Wiesmüller, K.-H., et al. (2008). Heterodimerization of TLR2 with
TLR1 or TLR6 expands the ligand spectrum but does not lead to differential signaling. J.
Leukoc. Biol. 83, 692–701.
Flores, A., Briand, J.F., Gadal, O., Andrau, J.C., Rubbi, L., Van Mullem, V., Boschiero, C.,
Goussot, M., Marck, C., Carles, C., et al. (1999). A protein-protein interaction map of yeast
RNA polymerase III. Proc. Natl. Acad. Sci. U. S. A. 96, 7815–7820.
Foureau, D.M., Mielcarz, D.W., Menard, L.C., Schulthess, J., Werts, C., Vasseur, V., Ryffel, B.,
Kasper, L.H., and Buzoni-Gatel, D. (2010). TLR9-dependent induction of intestinal alphadefensins by Toxoplasma gondii. J. Immunol. 184, 7022–7029.
Franke, A., Balschun, T., Karlsen, T.H., Sventoraityte, J., Nikolaus, S., Mayr, G., Domingues,
F.S., Albrecht, M., Nothnagel, M., Ellinghaus, D., et al. (2008). Sequence variants in IL10,
ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat. Genet. 40,
1319–1323.
Franke, A., McGovern, D.P.B., Barrett, J.C., Wang, K., Radford-Smith, G.L., Ahmad, T., Lees,
C.W., Balschun, T., Lee, J., Roberts, R., et al. (2010). Genome-wide meta-analysis increases
to 71 the number of confirmed Crohn’s disease susceptibility loci. Nat. Genet. 42, 1118–
1125.
Fre, S., Huyghe, M., Mourikis, P., Robine, S., Louvard, D., and Artavanis-Tsakonas, S. (2005).
Notch signals control the fate of immature progenitor cells in the intestine. Nature 435, 964–
968.
Fritzenwanker, J.H., Saina, M., and Technau, U. (2004). Analysis of forkhead and snail
expression reveals epithelial-mesenchymal transitions during embryonic and larval
development of Nematostella vectensis. Dev. Biol. 275, 389–402.
Gagné-Sansfaçon, J., Allaire, J.M., Jones, C., Boudreau, F., and Perreault, N. (2014). Loss of
sonic hedgehog leads to alterations in intestinal secretory cell maturation and autophagy.
PLoS One 9.
Gao, N., White, P., Doliba, N., Golson, M.L., Matschinsky, F.M., and Kaestner, K.H. (2007).
Foxa2 Controls Vesicle Docking and Insulin Secretion in Mature Beta Cells. Cell Metab. 6,
267–279.
Gao, N., LeLay, J., Vatamaniuk, M.Z., Rieck, S., Friedman, J.R., and Kaestner, K.H. (2008).
Dynamic regulation of Pdx1 enhancers by Foxa1 and Foxa2 is essential for pancreas
development. Genes Dev. 22, 3435–3448.
Gao, N., White, P., and Kaestner, K.H. (2009). Establishment of Intestinal Identity and Epithelial-

97

Mesenchymal Signaling by Cdx2. Dev. Cell 16, 588–599.
Gao, N., Le Lay, J., Qin, W., Doliba, N., Schug, J., Fox, A.J., Smirnova, O., Matschinsky, F.M.,
and Kaestner, K.H. (2010). Foxa1 and Foxa2 maintain the metabolic and secretory features
of the mature beta-cell. Mol. Endocrinol. (Baltimore, Md) 24, 1594–1604.
Garrison, W.D., Battle, M.A., Yang, C., Kaestner, K.H., Sladek, F.M., and Duncan, S.A. (2006).
Hepatocyte nuclear factor 4 alpha is essential for embryonic development of the mouse
colon. Gastroenterology 130, 1207–1220.
Gaudet, J., and Mango, S.E. (2002). Regulation of organogenesis by the Caenorhabditis elegans
FoxA protein PHA-4. Science 295, 821–825.
Gerbe, F., Van Es, J.H., Makrini, L., Brulin, B., Mellitzer, G., Robine, S., Romagnolo, B., Shroyer,
N.F., Bourgaux, J.F., Pignodel, C., et al. (2011). Distinct ATOH1 and Neurog3 requirements
define tuft cells as a new secretory cell type in the intestinal epithelium. J. Cell Biol. 192, 767–
780.
Gerbe, F., Legraverend, C., and Jay, P. (2012). The intestinal epithelium tuft cells: Specification
and function. Cell. Mol. Life Sci. 69, 2907–2917.
Gomez-Roman, N., Grandori, C., Eisenman, R.N., and White, R.J. (2003). Direct activation of
RNA polymerase III transcription by c-Myc. Nature 421, 290–294.
Gordon, M.D., and Nusse, R. (2006). Wnt signaling: Multiple pathways, multiple receptors, and
multiple transcription factors. J. Biol. Chem. 281, 22429–22433.
Gosalia, N., Yang, R., Kerschner, J.L., and Harris, a. (2015). FOXA2 regulates a network of
genes involved in critical functions of human intestinal epithelia cells. Physiol. Genomics
290–297.
Gregorieff, A., Pinto, D., Begthel, H., Destrée, O., Kielman, M., and Clevers, H. (2005).
Expression pattern of Wnt signaling components in the adult intestine. Gastroenterology 129,
626–638.
Grewal, S.S. (2014). Why should cancer biologists care about tRNAs? TRNA synthesis, mRNA
translation and the control of growth. Biochim. Biophys. Acta - Gene Regul. Mech. 1849,
898–907.
He, W., Wang, M.E.I.L.U.N., Jiang, H. a N.Q., Steppan, C.M., Shin, M.E., Thurnheer, M.C.,
Cebra, J.J., Lazar, M. a, and Wu, G.D. (2003). Bacterial Colonization Leads to the Colonic
Secretion of RELM-beta/FIZZ2, A Novel Goblet Cell–Specific Protein. Gastroenterology
5085, 1388–1397.
He, X.C., Zhang, J., Tong, W.-G., Tawfik, O., Ross, J., Scoville, D.H., Tian, Q., Zeng, X., He, X.,
Wiedemann, L.M., et al. (2004). BMP signaling inhibits intestinal stem cell self-renewal
through suppression of Wnt-beta-catenin signaling. Nat. Genet. 36, 1117–1121.
Heintzman, N.D., Hon, G.C., Hawkins, R.D., Kheradpour, P., Stark, A., Harp, L.F., Ye, Z., Lee,
L.K., Stuart, R.K., Ching, C.W., et al. (2009). Histone modifications at human enhancers
reflect global cell-type-specific gene expression. Nature 459, 108–112.
Hill, D.B., and Button, B. (2012). Mucins: Methods and Protocols.
Honke, K., and Taniguchi, N. (2002). Handbook of Glycosyltransferases and Related Genes.
Handb. Glycosyltransferases Relat. Genes 2, 102–106.
Hooper, L. V. (2004). Bacterial contributions to mammalian gut development. Trends Microbiol.

98

12, 129–134.
Hooper, L. V, Stappenbeck, T.S., Hong, C. V, and Gordon, J.I. (2003). Angiogenins: a new class
of microbicidal proteins involved in innate immunity. Nat. Immunol. 4, 269–273.
Howitt, M.R., Lavoie, S., Michaud, M., Blum, A.M., Tran, S.V., Weinstock, J.V., Gallini, C.A.,
Redding, K., Margolskee, R.F., Osborne, L.C. and Artis, D. (2016). Tuft cells, tastechemosensory cells,orchestrate parasite type 2 immunityin the gut. Science (80-. ). 351,
1329–1333.
Huang, P., Zhang, L., Gao, Y., He, Z., Yao, D., Wu, Z., Cen, J., Chen, X., Liu, C., Hu, Y., et al.
(2014). Direct reprogramming of human fibroblasts to functional and expandable
hepatocytes. Cell Stem Cell 14, 370–384.
Hugot, J.P., Chamaillard, M., Zouali, H., Lesage, S., Cézard, J.P., Belaiche, J., Almer, S., Tysk,
C., O’Morain, C. a, Gassull, M., et al. (2001). Association of NOD2 leucine-rich repeat
variants with susceptibility to Crohn’s disease. Nature 411, 599–603.
Inoue, R., Tsuruta, T., Nojima, I., Nakayama, K., Tsukahara, T., and Yajima, T. (2008). Postnatal
changes in the expression of genes for cryptdins 1-6 and the role of luminal bacteria in
cryptdin gene expression in mouse small intestine. FEMS Immunol. Med. Microbiol. 52, 407–
416.
Itzkowitz, S., Kjeldsen, T., Friera, A., Hakomori, S., Yang, U.S., and Kim, Y.S. (1991). Expression
of Tn, sialosyl Tn, and T antigens in human pancreas. Gastroenterology 100, 1691–1700.
Iwafuchi-Doi, M., Donahue, G., Kakumanu, A., Watts, J.A., Mahony, S., Pugh, B.F., Lee, D.,
Kaestner, K.H., and Zaret, K.S. (2016). The Pioneer Transcription Factor FoxA Maintains an
Accessible Nucleosome Configuration at Enhancers for Tissue-Specific Gene Activation. Mol.
Cell 62, 79–91.
Iwai, T., Inaba, N., Naundorf, A., Zhang, Y., Gotoh, M., Iwasaki, H., Kudo, T., Togayachi, A.,
Ishizuka, Y., Nakanishi, H., et al. (2002). Molecular cloning and characterization of a novel
UDP-GlcNAc:GalNAc-peptide beta1,3-N-acetylglucosaminyltransferase (beta 3Gn-T6), an
enzyme synthesizing the core 3 structure of O-glycans. J. Biol. Chem. 277, 12802–12809.
Jackson, B.C., Carpenter, C., Nebert, D.W., and Vasiliou, V. (2010). Update of human and mouse
forkhead box (FOX) gene families. Hum. Genomics 4, 345–352.
Jarczak, J., Kościuczuk, E.M., Lisowski, P., Strzałkowska, N., Jóźwik, A., Horbańczuk, J.,
Krzyzewski, J., Zwierzchowski, L., and Bagnicka, E. (2013). Defensins: Natural component of
human innate immunity. Hum. Immunol. 74, 1069–1079.
Jensen, J., Pedersen, E.E., Galante, P., Hald, J., Heller, R.S., Ishibashi, M., Kageyama, R.,
Guillemot, F., Serup, P., and Madsen, O.D. (2000). Control of endodermal endocrine
development by Hes-1. Nat. Genet. 24, 36–44.
Johansson, M.E. V, Phillipson, M., Petersson, J., Velcich, A., Holm, L., Hansson, G.C.,
Petersson, J., Velcich, A., Holm, L., Hansson, G.C., et al. (2008). The inner of the two Muc2
mucin-dependent mucus layers in colon is devoid of bacteria. Proc. Natl. Acad. Sci. U. S. A.
105, 15064–15069.
Johansson, M.E. V, Larsson, J.M.H., and Hansson, G.C. (2011). The two mucus layers of colon
are organized by the MUC2 mucin, whereas the outer layer is a legislator of host-microbial
interactions. Proc. Natl. Acad. Sci. U. S. A. 108 Suppl, 4659–4665.
Jostins, L., Ripke, S., Weersma, R.K., Duerr, R.H., McGovern, D.P., Hui, K.Y., Lee, J.C.,
Schumm, L.P., Sharma, Y., Anderson, C.A., et al. (2012). Host-microbe interactions have

99

shaped the genetic architecture of inflammatory bowel disease. Nature 491, 119–124.
Kaestner, K.H., Hiemisch, H., Luckow, B., and Schütz, G. (1994). The HNF-3 gene family of
transcription factors in mice: gene structure, cDNA sequence, and mRNA distribution.
Genomics 20, 377–385.
Kaestner, K.H., Hiemisch, H., and Schütz, G. (1998). Targeted disruption of the gene encoding
hepatocyte nuclear factor 3gamma results in reduced transcription of hepatocyte-specific
genes. Mol. Cell. Biol. 18, 4245–4251.
Kaestner, K.H., Katz, J., Liu, Y., Drucker, D.J., and Schütz, G. (1999). Inactivation of the winged
helix transcription factor HNF3-alpha affects glucose homeostasis and islet glucagon gene
expression in vivo. Genes Dev. 13, 495–504.
Kaestner, K.H., Knöchel, W., Martínez, D.E., Kno, W., and Martı, D.E. (2000). Unified
nomenclature for the winged helix / forkhead transcription factors. Genes Dev. 14, 142–146.
Kalb, J.M., Lau, K.K., Goszczynski, B., Fukushige, T., Moons, D., Okkema, P.G., and McGhee,
J.D. (1998). pha-4 is Ce-fkh-1, a fork head/HNF-3alpha,beta,gamma homolog that functions
in organogenesis of the C. elegans pharynx. Development 125, 2171–2180.
Kaplan, G.G., and Ng, S.C. (2016). Understanding and Preventing the Global Increase of
Inflammatory Bowel Disease. Gastroenterology.
Kelly, R.J., Rouquier, S., Giorgi, D., Lennon, G.G., and Lowe, J.B. (1995). Sequence and
expression of a candidate for the human Secretor blood group α(1,2)fucosyltransferase gene
(FUT2). Homozygosity for an enzyme- inactivating nonsense mutation commonly correlates
with the non-secretor phenotype. J. Biol. Chem. 270, 4640–4649.
Kim, J.J., Shajib, M.S., Manocha, M.M., and Khan, W.I. (2012). Investigating Intestinal
Inflammation in DSS-induced Model of IBD. J. Vis. Exp. 1–7.
Kopan, R., and Ilagan, M.X.G. (2009). The Canonical Notch Signaling Pathway: Unfolding the
Activation Mechanism. Cell 137, 216–233.
Kosinski, C., Stange, D.E., Xu, C., Chan, A.S., Ho, C., Yuen, S.T., Mifflin, R.C., Powell, D.W.,
Clevers, H., Leung, S.Y., et al. (2010). Indian hedgehog regulates intestinal stem cell fate
through epithelial-mesenchymal interactions during development. Gastroenterology 139,
893–903.
Krämer, A., Green, J., Pollard, J., and Tugendreich, S. (2014). Causal analysis approaches in
Ingenuity Pathway Analysis. Bioinformatics 30, 523–530.
Krimi, R.B., Kotelevets, L., Dubuquoy, L., Plaisancié, P., Walker, F., Lehy, T., Desreumaux, P.,
Van Seuningen, I., Chastre, E., Forgue-Lafitte, M.E., et al. (2008). Resistin-like molecule beta
regulates intestinal mucous secretion and curtails TNBS-induced colitis in mice. Inflamm.
Bowel Dis. 14, 931–941.
Kuhn, R., Lohler, J., Rennick, D., Rajewsky, K., and Muller, W. (1993). Interleukin-10-Deficient
Mice Develop Chronic Enterocolitis. Cell 75, 263–274.
Kuhnert, F., Davis, C.R., Wang, H.-T., Chu, P., Lee, M., Yuan, J., Nusse, R., and Kuo, C.J.
(2004). Essential requirement for Wnt signaling in proliferation of adult small intestine and
colon revealed by adenoviral expression of Dickkopf-1. Proc. Natl. Acad. Sci. U. S. A. 101,
266–271.
Lai, E., Prezioso, V.R., Smith, E., Litvin, O., Costa, R.H., and Darnell, J.E. (1990). HNF-3A, a
hepatocyte-enriched transcription factor of novel structure is regulated transcriptionally.

100

Genes Dev. 4, 1427–1436.
Landrieux, E., Alic, N., Ducrot, C., Acker, J., Riva, M., and Carles, C. (2006). A subcomplex of
RNA polymerase III subunits involved in transcription termination and reinitiation. EMBO J 25,
118–128.
de Lau, W., Barker, N., Low, T.Y., Koo, B.-K., Li, V.S.W., Teunissen, H., Kujala, P., Haegebarth,
A., Peters, P.J., van de Wetering, M., et al. (2011). Lgr5 homologues associate with Wnt
receptors and mediate R-spondin signalling. Nature 476, 293–297.
Lee, C.S., Sund, N.J., Vatamaniuk, M.Z., Matschinsky, F.M., Stoffers, D.A., and Kaestner, K.H.
(2002). Foxa2 controls Pdx1 gene expression in pancreatic beta-cells in vivo. Diabetes 51,
2546–2551.
Lee, C.S., Friedman, J.R., Fulmer, J.T., and Kaestner, K.H. (2005). The initiation of liver
development is dependent on Foxa transcription factors. Nature 435, 944–947.
Levine, B., and Deretic, V. (2007). Unveiling the roles of autophagy in innate and adaptive
immunity. Nat. Rev. Immunol. 7, 767–777.
Li, Z., White, P., Tuteja, G., Rubins, N., Sackett, S., and H, K. (2009). Foxa1 and Foxa2 Control
Bile Duct Development. Development 119, 1–7.
Lin, L., Miller, C.T., Contreras, J.I., Prescott, M.S., Dagenais, S.L., Wu, R., Yee, J., Orringer,
M.B., Misek, D.E., Hanash, S.M., et al. (2002). The hepatocyte nuclear factor 3 alpha gene,
HNF3alpha (FOXA1), on chromosome band 14q13 is amplified and overexpressed in
esophageal and lung adenocarcinomas. Cancer Res. 62, 5273–5279.
Liu, J.Z., van Sommeren, S., Huang, H., Ng, S.C., Alberts, R., Takahashi, A., Ripke, S., Lee, J.C.,
Jostins, L., Shah, T., et al. (2015). Association analyses identify 38 susceptibility loci for
inflammatory bowel disease and highlight shared genetic risk across populations. Nat. Genet.
47, 979–989.
Madara, J.L. (1982). Cup Cells: Structure and Distribution of a Unique Class of Epithelial Cells in
Guinea Pig, Rabbit, and Monkey Small Intestine. Gastroenterology 83, 981–994.
Madison, B.B., Dunbar, L., Qiao, X.T., Braunstein, K., Braunstein, E., and Gumucio, D.L. (2002).
cis elements of the villin gene control expression in restricted domains of the vertical (crypt)
and horizontal (duodenum, cecum) axes of the intestine. J. Biol. Chem. 277, 33275–33283.
Madison, B.B., Braunstein, K., Kuizon, E., Portman, K., Qiao, X.T., and Gumucio, D.L. (2005).
Epithelial hedgehog signals pattern the intestinal crypt-villus axis. Development 132, 279–
289.
Mashimo, H., Wu, D.-C., Podolsky, D.K., and Fishman, M.C. (1996). Impaired Defense of
Intestinal Mucosa in Mice Lacking Intestinal Trefoil Factor. Science (80-. ). 274, 262–265.
Mathan, M., Moxey, P.C., and Trier, J.S. (1976). Morphogenesis of fetal rat duodenal villi. Am. J.
Anat. 146, 73–92.
McGovern, D.P.B., Jones, M.R., Taylor, K.D., Marciante, K., Yan, X., Dubinsky, M., Ippoliti, A.,
Vasiliauskas, E., Berel, D., Derkowski, C., et al. (2010). Fucosyltransferase 2 (FUT2) nonsecretor status is associated with Crohn’s disease. Hum. Mol. Genet. 19, 3468–3476.
McKnight, K.D., Hou, J., and Hoodless, P.A. (2010). Foxh1 and Foxa2 are not required for
formation of the midgut and hindgut definitive endoderm. Dev. Biol. 337, 471–481.
Metcalfe, C., Kljavin, N.M., Ybarra, R., and De Sauvage, F.J. (2014). Lgr5+ stem cells are

101

indispensable for radiation-induced intestinal regeneration. Cell Stem Cell 14, 149–159.
Michels, A. a, Robitaille, A.M., Buczynski-Ruchonnet, D., Hodroj, W., Reina, J.H., Hall, M.N., and
Hernandez, N. (2010). mTORC1 directly phosphorylates and regulates human MAF1. Mol.
Cell. Biol. 30, 3749–3757.
Mombaerts, P. (1993). Spontaneous development of inflammatory bowel disease in T cell
receptor mutant mice. Cell 75, 274.
Morris, G., Beck, P., Herridge, M., Depew, W., Szewczuk, M., and Wallace, J. (1989). Hapteninduced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 96,
795–803.
Mumm, J.S., and Kopan, R. (2000). Notch Signaling : From the Outside In. 165, 151–165.
Neutra, M.R. (1998). Current concepts in mucosal immunity. V Role of M cells in transepithelial
transport of antigens and pathogens to the mucosal immune system. Am. J. Physiol. 274,
G785–G791.
Norton, W.H., Mangoli, M., Lele, Z., Pogoda, H.-M., Diamond, B., Mercurio, S., Russell, C.,
Teraoka, H., Stickney, H.L., Rauch, G.-J., et al. (2005). Monorail/Foxa2 regulates floorplate
differentiation and specification of oligodendrocytes, serotonergic raphé neurones and cranial
motoneurones. Development 132, 645–658.
Okayasu, I., Hatakeyama, S., Yamada, M., Ohkusa, T., Inagaki, Y., and Nakaya, R. (1990). A
novel method in the induction of reliable experimental acute and chronic ulcerative colitis in
mice. Gastroenterology 98, 694–702.
Orholm, M., Binder, V., Sorensen, T.I., Rasmussen, L.P., and Kyvik, K.O. (2000). Concordance of
inflammatory bowel disease among Danish twins. Results of a nationwide study. Scand J
Gastroenterol 35, 1075–1081.
Orioli, A., Praz, V., Lhôte, P., Hernandez, N., Lhote, P., and Hernandez, N. (2016). Human MAF1
targets and represses active RNA polymerase III genes by preventing recruitment rather than
inducing long-term transcriptional arrest. Genome Res. 26, 624–634.
Patsos, G., and Corfield, A. (2009). Management of the human mucosal defensive barrier:
Evidence for glycan legislation. Biol. Chem. 390, 581–590.
Pavon-Eternod, M., Gomes, S., Geslain, R., Dai, Q., Rosner, M.R., and Pan, T. (2009). tRNA
over-expression in breast cancer and functional consequences. Nucleic Acids Res. 37, 7268–
7280.
Pickard, J.M., Maurice, C.F., Kinnebrew, M.A., Abt, M.C., Schenten, D., Golovkina, T. V.,
Bogatyrev, S.R., Ismagilov, R.F., Pamer, E.G., Turnbaugh, P.J., et al. (2014). Rapid
fucosylation of intestinal epithelium sustains host–commensal symbiosis in sickness. Nature
514, 638–641.
Podolsky, D.K., and Fournier, D.A. (1988). Emergence of antigenic glycoprotein structures in
ulcerative colitis detected through monoclonal antibodies. Gastroenterology 95, 371–378.
Van Der Post, S., Subramani, D.B., Bac̈kström, M., Johansson, M.E. V, Vester-Christensen,
M.B., Mandel, U., Bennett, E.P., Clausen, H., Dahleń, G., Sroka, A., et al. (2013). Sitespecific O-glycosylation on the MUC2 mucin protein inhibits cleavage by the Porphyromonas
gingivalis secreted cysteine protease (RgpB). J. Biol. Chem. 288, 14636–14646.
Ren, B., Malefyt, D.W., Abrams, J., Bennett, B., Figdor, C.G., and Vries, J.E. De (1991).
Published November 1, 1991. 174.

102

Rioux, J.D., Xavier, R.J., Taylor, K.D., Silverberg, M.S., Goyette, P., Huett, A., Green, T., Kuballa,
P., Barmada, M.M., Datta, L.W., et al. (2007). Genome-wide association study identifies new
susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat.
Genet. 39, 596–604.
Roberts, D.N., Stewart, A.J., Huff, J.T., and Cairns, B.R. (2003). The RNA polymerase III
transcriptome revealed by genome-wide localization and activity-occupancy relationships.
Proc. Natl. Acad. Sci. U. S. A. 100, 14695–14700.
Rodríguez, C.I., Buchholz, F., Galloway, J., Sequerra, R., Kasper, J., Ayala, R., Stewart, a F.,
and Dymecki, S.M. (2000). High-efficiency deleter mice show that FLPe is an alternative to
Cre-loxP. Nat. Genet. 25, 139–140.
Roth, M.P., Petersen, G.M., McElree, C., Vadheim, C.M., Panish, J.F., and Rotter, J.I. (1989).
Familial empiric risk estimates of inflammatory bowel disease in Ashkenazi Jews.
Gastroenterology 96, 1016–1020.
Russell, R.K., and Satsangi, J. (2004). IBD: A family affair. Best Pract. Res. Clin. Gastroenterol.
18, 525–539.
Sadlack, B., Merz, H., Schorle, H., Schimpl, A., Feller, A.C., and Horak, I. (1993). Ulcerative
colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 75, 253–261.
Sakamori, R., Das, S., Yu, S., Feng, S., Stypulkowski, E., Guan, Y., Douard, V., Tang, W.,
Ferraris, R.P., Harada, A., et al. (2012). Cdc42 and Rab8a are critical for intestinal stem cell
division, survival, and differentiation in mice. J. Clin. Invest. 122, 1052–1065.
Salzman, N.H., Hung, K., Haribhai, D., Chu, H., Karlsson-Sjöberg, J., Amir, E., Teggatz, P.,
Barman, M., Hayward, M., Eastwood, D., et al. (2010). Enteric defensins are essential
regulators of intestinal microbial ecology. Nat. Immunol. 11, 76–83.
De Santa Barbara, P., van den Brink, G.R., and Roberts, D.J. (2003). Development and
differentiation of the intestinal epithelium. Cell. Mol. Life Sci. 60, 1322–1332.
Sato, T., Vries, R.G., Snippert, H.J., van de Wetering, M., Barker, N., Stange, D.E., van Es, J.H.,
Abo, A., Kujala, P., Peters, P.J., et al. (2009). Single Lgr5 stem cells build crypt-villus
structures in vitro without a mesenchymal niche. Nature 459, 262–265.
Schloss, P.D., Schubert, A.M., Zackular, J.P., Iverson, K.D., Young, V.B., and Petrosino, J.F.
(2012). Stabilization of the murine gut microbiome following weaning. Gut Microbes 3, 383–
393.
Schmidt, G.H., Winton, D.J., and Ponder, B. a (1988). Development of the pattern of cell renewal
in the crypt-villus unit of chimaeric mouse small intestine. Development 103, 785–790.
Schwerbrock, N.M.J., Makkink, M.K., van der Sluis, M., Büller, H. a, Einerhand, A.W.C., Sartor,
R.B., and Dekker, J. (2004). Interleukin 10-deficient mice exhibit defective colonic Muc2
synthesis before and after induction of colitis by commensal bacteria. Inflamm. Bowel Dis. 10,
811–823.
Shroyer, N.F., Helmrath, M.A., Wang, V.Y.C., Antalffy, B., Henning, S.J., and Zoghbi, H.Y.
(2007). Intestine-Specific Ablation of Mouse atonal homolog 1 (Math1) Reveals a Role in
Cellular Homeostasis. Gastroenterology 132, 2478–2488.
Silberg, D.G., Swain, G.P., Suh, E.R., and Traber, P.G. (2000). Cdx1 and Cdx2 expression during
intestinal development. Gastroenterology 119, 961–971.
Silberg, D.G., Sullivan, J., Kang, E., Swain, G.P., Moffett, J., Sund, N.J., Sackett, S.D., and

103

Kaestner, K.H. (2002). Cdx2 ectopic expression induces gastric intestinal metaplasia in
transgenic mice. Gastroenterology 122, 689–696.
Singh, K., Carey, M., Saragosti, S., and Botchan, M. (1985). Expression of enhanced levels of
small RNA polymerase III transcripts encoded by the B2 repeats in simian virus 40transformed mouse cells. Nature 314, 553–556.
Singh, T., Levine, A.P., Smith, P.J., Smith, A.M., Segal, A.W., and Barrett, J.C. (2015).
Characterization of expression quantitative trait loci in the human colon. Inflamm. Bowel Dis.
21, 251–256.
van der Sluis, M., Vincent, A., Bouma, J., Male, A.K. Van, van Goudoever, J.B., Renes, I.B., and
Van Seuningen, I. (2008). Forkhead box transcription factors Foxa1 and Foxa2 are important
regulators of Muc2 mucin expression in intestinal epithelial cells. Biochem. Biophys. Res.
Commun. 369, 1108–1113.
Van der Sluis, M., De Koning, B.A.E., De Bruijn, A.C.J.M., Velcich, A., Meijerink, J.P.P., Van
Goudoever, J.B., Buller, H.A., Dekker, J., Van Seuningen, I., Renes, I.B., et al. (2006). Muc2Deficient Mice Spontaneously Develop Colitis, Indicating That MUC2 Is Critical for Colonic
Protection. Gastroenterology 131, 117–129.
Stappenbeck, T.S., Hooper, L. V, and Gordon, J.I. (2002). Developmental regulation of intestinal
angiogenesis by indigenous microbes via Paneth cells. Proc. Natl. Acad. Sci. U. S. A. 99,
15451–15455.
Steppan, C.M., Brown, E.J., Wright, C.M., Bhat, S., Banerjee, R.R., Dai, C.Y., Enders, G.H.,
Silberg, D.G., Wen, X., Wu, G.D., et al. (2001). A family of tissue-specific resistin-like
molecules. Proc. Natl. Acad. Sci. U. S. A. 98, 502–506.
Sternini, C., Anselmi, L., and Rozengurt, E. (2008). Enteroendocrine cells: a site of “taste” in
gastrointestinal chemosensing. Curr. Opin. Endocrinol. Diabetes. Obes. 15, 73–78.
Strober, W., Fuss, I.J., and Blumberg, R.S. (2002). The Immunology of Mucosal Models of
Inflammation. Annu. Rev. Immunol. 20, 495–549.
Su, L.K., Kinzler, K.W., Vogelstein, B., Preisinger, A.C., Moser, A.R., Luongo, C., Gould, K.A.,
and Dove, W.F. (1992). Multiple intestinal neoplasia caused by a mutation in the murine
homolog of the APC gene. Science 256, 668–670.
Sund, N.J., Vatamaniuk, M.Z., Casey, M., Ang, S.W., Magnuson, M.A., Stoffers, D.A.,
Matschinsky, F.M., and Kaestner, K.H. (2001). Tissue-specific deletion of Foxa2 in pancreatic
β cells results in hyperinsulinemic hypoglycemia. Genes Dev. 15, 1706–1715.
Tandon, B., Magotra, M., Saraya, A., and Ramalingaswami, V. (1968). Small Intestine in Protein
Malnutrition. Am. J. Clin. Nutr. 21, 813–819.
Terahara, K., Nochi, T., Yoshida, M., Takahashi, Y., Goto, Y., Hatai, H., Kurokawa, S., Jang,
M.H., Kweon, M.N., Domino, S.E., et al. (2011). Distinct fucosylation of M cells and epithelial
cells by Fut1 and Fut2, respectively, in response to intestinal environmental stress. Biochem.
Biophys. Res. Commun. 404, 822–828.
Torres, J., Mehandru, S., Colombel, J.-F., and Peyrin-Biroulet, L. (2016). Crohn’s disease. Lancet
6736, 1–15.
Tosh, D., and Slack, J.M.W. (2002). THEIR PHENOTYPE. 3.
Tsukamoto, T., Inada, K., Tanaka, H., Mizoshita, T., Mihara, M., Ushijima, T., Yamamura, Y.,
Nakamura, S., and Tatematsu, M. (2004). Down-regulation of a gastric transcription factor,

104

Sox2, and ectopic expression of intestinal homeobox genes, Cdx1 and Cdx2: Inverse
correlation during progression from gastric/intestinal-mixed to complete intestinal metaplasia.
J. Cancer Res. Clin. Oncol. 130, 135–145.
Tuteja, G., White, P., Schug, J., and Kaestner, K.H. (2009). Extracting transcription factor targets
from ChIP-Seq data. Nucleic Acids Res. 37.
Vatamaniuk, M.Z., Gupta, R.K., Lantz, K.A., Doliba, N.M., Matschinsky, F.M., and Kaestner, K.H.
(2006). Foxa1-deficient mice exhibit impaired insulin secretion due to uncoupled oxidative
phosphorylation. Diabetes 55, 2730–2736.
Velcich, A. (2002). Colorectal Cancer in Mice Genetically Deficient in the Mucin Muc2. Science
(80-. ). 295, 1726–1729.
Verzi, M.P., Shin, H., He, H.H., Sulahian, R., Meyer, C.A., Montgomery, R.K., Fleet, J.C., Brown,
M., Liu, X.S., and Shivdasani, R.A. (2010). Differentiation-Specific Histone Modifications
Reveal Dynamic Chromatin Interactions and Partners for the Intestinal Transcription Factor
CDX2. Dev. Cell 19, 713–726.
Verzi, M.P., Shin, H., San Roman, A.K., Liu, X.S., and Shivdasani, R.A. (2012). Intestinal Master
Transcription Factor CDX2 Controls Chromatin Access for Partner Transcription Factor
Binding. Mol. Cell. Biol. 33, 281–292.
Wan, H., Kaestner, K.H., Ang, S.-L., Ikegami, M., Finkelman, F.D., Stahlman, M.T., Fulkerson,
P.C., Rothenberg, M.E., and Whitsett, J. a (2004). Foxa2 regulates alveolarization and goblet
cell hyperplasia. Development 131, 953–964.
Wan, H., Dingle, S., Xu, Y., Besnard, V., Kaestner, K.H., Ang, S.L., Wert, S., Stahlman, M.T., and
Whitsett, J.A. (2005). Compensatory roles of Foxal and Foxa2 during lung morphogenesis. J.
Biol. Chem. 280, 13809–13816.
Wang, D.H., Tiwari, A., Kim, M.E., Clemons, N.J., Regmi, N.L., Hodges, W.A., Berman, D.M.,
Montgomery, E.A., Watkins, D.N., Zhang, X., et al. (2014). Hedgehog signaling regulates
FOXA2 in esophageal embryogenesis and Barrett ’ s metaplasia. 124, 3767–3780.
Wang, Y., Huang, D., Chen, K.-Y., Cui, M., Wang, W., Huang, X., Awadellah, A., Li, Q.,
Friedman, A., Xin, W.W., et al. (2016). Fucosylation Deficiency in Mice Leads to Colitis and
Adenocarcinoma. Gastroenterology 1–13.
Wangensteen, K.J., Zhang, S., Greenbaum, L.E., and Kaestner, K.H. (2015). A genetic screen
reveals Foxa3 and TNFR1 as key regulators of liver repopulation. Genes Dev. 29, 904–909.
Watts, J.A., Zhang, C., Klein-Szanto, A.J., Kormish, J.D., Fu, J., Zhang, M.Q., and Zaret, K.S.
(2011). StuWatts, J. A., Zhang, C., Klein-Szanto, A. J., Kormish, J. D., Fu, J., Zhang, M. Q., &
Zaret, K. S. (2011). Study of foxA pioneer factor at silent genes reveals Rfx-repressed
enhancer at Cdx2 and a potential indicator of esophageal adenocarcinoma develo. PLoS
Genet. 7.
Weigel, D., and Jäckle, H. (1990). The fork head domain: a novel DNA binding motif of eukaryotic
transcription factors? Cell 63, 455–456.
Weigel, D., Jürgens, G., Küttner, F., Seifert, E., and Jäckle, H. (1989). The homeotic gene fork
head encodes a nuclear protein and is expressed in the terminal regions of the Drosophila
embryo. Cell 57, 645–658.
Weinstein, D.C., Ruiz i Altaba, A., Chen, W.S., Hoodless, P., Prezioso, V.R., Jessell, T.M., and
Darnell, J.E. (1994). The winged-helix transcription factor HNF-3 beta is required for
notochord development in the mouse embryo. Cell 78, 575–588.

105

White, R.J. (2004). RNA polymerase III transcription and cancer. Oncogene 23, 3208–3216.
White, R.J. (2008). RNA polymerases I and III, non-coding RNAs and cancer. Trends Genet. 24,
622–629.
White, R.J. (2011). Transcription by RNA polymerase III: more complex than we thought. Nat.
Rev. Genet. 12, 459–463.
White, R.J., Trouche, D., Martin, K., Jackson, S.P., and Kouzarides, T. (1996). Repression of
RNA polymerase III transcription by the retinoblastoma protein. Nature 382, 88–90.
Winter, A.G., Sourvinos, G., Allison, S.J., Tosh, K., Scott, P.H., Spandidos, D.A., and White, R.J.
(2000). RNA polymerase III transcription factor TFIIIC2 is overexpressed in ovarian tumors.
Proc. Natl. Acad. Sci. U. S. A. 97, 12619–12624.
Wu, L., Pan, J., Thoroddsen, V., Wysong, D.R., Blackman, R.K., Bulawa, C.E., Gould, A.E.,
Ocain, T.D., Dick, L.R., Errada, P., et al. (2003). Novel small-molecule inhibitors of RNA
polymerase III. Eukaryot. Cell 2, 256–264.
Yang, K., Popova, N. V., Wan, C.Y., Lozonschi, I., Tadesse, S., Kent, S., Bancroft, L., Matise, I.,
Cormier, R.T., Scherer, S.J., et al. (2008). Interaction of Muc2 and Apc on Wnt signaling and
in intestinal tumorigenesis: Potential role of chronic inflammation. Cancer Res. 68, 7313–
7322.
Yang, Q., Bermingham, N. a, Finegold, M.J., and Zoghbi, H.Y. (2001). Requirement of Math1 for
secretory cell lineage commitment in the mouse intestine. Science 294, 2155–2158.
Ye, D.Z., and Kaestner, K.H. (2009). Foxa1 and Foxa2 Control the Differentiation of Goblet and
Enteroendocrine L- and D-Cells in Mice. Gastroenterology 137, 2052–2062.
Yee, N.S., Gong, W., Huang, Y., Lorent, K., Dolan, A.C., Maraia, R.J., and Pack, M. (2007).
Mutation of RNA Pol III subunit rpc2/polr3b leads to deficiency of subunit Rpc11 and disrupts
zebrafish digestive development. PLoS Biol. 5, 2484–2492.
Yee, N.S., Zhou, W., Chun, S.G., Liang, I.-C., and Yee, R.K. (2012). Targeting developmental
regulators of zebrafish exocrine pancreas as a therapeutic approach in human pancreatic
cancer. Biol. Open 1, 295–307.
Zhang, Y., Liu, T., Meyer, C.A., Eeckhoute, J., Johnson, D.S., Bernstein, B.E., Nussbaum, C.,
Myers, R.M., Brown, M., Li, W., et al. (2008). Model-based analysis of ChIP-Seq (MACS).
Genome Biol 9, R137.
Zhou, Y., Goodenbour, J.M., Godley, L.A., Wickrema, A., and Pan, T. (2009). High levels of tRNA
abundance and alteration of tRNA charging by bortezomib in multiple myeloma. Biochem.
Biophys. Res. Commun. 385, 160–164.
Zhu, G., Muller, E.G., Amacher, S.L., Northrop, J.L., and Davis, T.N. (1993). A dosage-dependent
suppressor of a temperature-sensitive calmodulin mutant encodes a protein related to the
fork head family of DNA-binding proteins. Mol. Cell. Biol. 13, 1779–1787.

106

